[
    {
        "content": "* Teva announces prescription copay savings program for generic Gleevec\u00ae tablets in the United States Source text for Eikon: Further company coverage:",
        "date": "11152017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces prescription copay savings program for generic Gleevec tablets in the U.S. "
    },
    {
        "content": "NEW YORK Allergan Plc  said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries  during the first quarter of 2018  as it starts to unwind its position in the struggling generic drugmaker.",
        "date": "11132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Allergan to sell a quarter of its Teva stake in first quarter of 2018 "
    },
    {
        "content": "NEW YORK  Nov 13 Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel's Teva Pharmaceutical Industries during the first quarter of 2018  as it starts to unwind its position in the struggling generic drugmaker.",
        "date": "11132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Allergan to sell a quarter of its Teva stake in Q1 2018 "
    },
    {
        "content": "* Doubts about U.S. tax plan  other news stoke sector sell-off",
        "date": "11102017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-U.S. junk bond sector ends rough week on calmer note "
    },
    {
        "content": "Mylan NV  on Monday raised its full-year forecast and  expects sales from its recently approved version of Teva's  blockbuster multiple sclerosis treatment Copaxone to offset declining revenue from its EpiPen emergency allergy injector.",
        "date": "11062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Mylan raises forecast on strength of generic Copaxone "
    },
    {
        "content": "* Raises lower end of 2017 revenue  adjusts earnings forecasts",
        "date": "11062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Mylan raises forecast on strength of generic Copaxone "
    },
    {
        "content": "JERUSALEM Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries   according to Israeli media reports.",
        "date": "11052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Billionaire Blavatnik weighs big share purchase in Teva Pharm: reports "
    },
    {
        "content": "JERUSALEM  Nov 5 Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries  according to Israeli media reports.",
        "date": "11052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Billionaire Blavatnik weighs big share purchase in Teva Pharm-reports "
    },
    {
        "content": "JERUSALEM  Nov 5 Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries  according to Israeli media reports.",
        "date": "11052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Billionaire Blavatnik weighs big share purchase in Teva Pharm-reports "
    },
    {
        "content": "A federal appeals court on Wednesday invalidated a Bayer AG patent on its erectile dysfunction treatment Staxyn  clearing the way for Teva Pharmaceutical Industries Ltd to launch a generic version of the drug.",
        "date": "11012017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva wins court decision nixing Bayer patent on ED drug Staxyn "
    },
    {
        "content": "* U.S. Court ruled in Teva's favor in patent litigation involving its ANDA directed to generic version of Valeant's uceris (budesonide ER) tablets\u200b Source text for Eikon: Further company coverage:",
        "date": "10312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva wins generic Uceris patent trial "
    },
    {
        "content": "JERUSALEM Teva Pharmaceutical Industries   the world's biggest generic medicine maker  came under investor and market pressure on Thursday after saying it would miss 2017 profit forecasts.",
        "date": "11022017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva shares topple on profit warning  uncertain future "
    },
    {
        "content": "Nov 1 Botox-maker Allergan Plc on Wednesday said it will begin to sell off its nearly 10 percent stake in Teva Pharmaceutical Industries  which has lost 60 percent of its value so far this year.",
        "date": "11012017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Allergan to begin selling its 10 percent stake in Teva "
    },
    {
        "content": "* New CEO says debt reduction a key priority (Releads  adds chairman/CFO comment  updates share reaction)",
        "date": "11022017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Teva shares topple on profit warning  uncertain future "
    },
    {
        "content": "* Generic medicines revenues in Q3 of 2017 were $3.0 billion  a decrease of 8% compared to Q3 of 2016\u200b",
        "date": "11022017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical Q3 GAAP earnings per share $0.52 "
    },
    {
        "content": "JERUSALEM  Nov 2 Debt-ridden Israeli drugmaker Teva Pharmaceutical Industries reported lower than expected profit in the third quarter and sharply lowered its 2017 estimates  as the company continues to be hurt by weak U.S. generic medicine sales.",
        "date": "11022017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva falls short on Q3 profit  slashes 2017 estimates again "
    },
    {
        "content": "* Allergan Plc\u200b announces its intention to begin process of selling the ordinary shares of Teva Pharmaceutical Industries in a prudent and orderly manner",
        "date": "11012017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan says to begin process of sale of its Teva Pharmaceutical shares "
    },
    {
        "content": "* Mylan wins UK court ruling related to Copaxone\u00ae 40 mg/ml patent",
        "date": "10262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Mylan wins UK court ruling related to Copaxone 40 mg/ml patent "
    },
    {
        "content": "BOSTON  Oct 25 Teva Pharmaceutical Industries Ltd has filed a patent infringement lawsuit seeking to block Eli Lilly and Co from bringing its migraine drug galcanezumab to market in the United States.",
        "date": "10252017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva accuses Lilly in U.S. court of infringing migraine drug patents "
    },
    {
        "content": "* Teva announces submission of biologics license application for Fremanezumab to the U.S. FDA",
        "date": "10172017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces submission of biologics license application for Fremanezumab to U.S. FDA "
    },
    {
        "content": "* BioDelivery Sciences announces patent litigation settlement agreement with Teva",
        "date": "10122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva "
    },
    {
        "content": "LONDON Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe  just two days after Mylan NV won U.S. approval to sell  cheaper versions of the medicine in the world's largest market.",
        "date": "10052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva's Copaxone faces generic competition in Europe after U.S. hit "
    },
    {
        "content": "LONDON  Oct 5 Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe  just two days after Mylan NV won U.S. approval to sell  cheaper versions of the medicine in the world's largest market.",
        "date": "10052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva's Copaxone faces generic competition in Europe after U.S. hit "
    },
    {
        "content": "Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.",
        "date": "10042017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Mylan surges  Teva slumps after FDA approves Copaxone copy "
    },
    {
        "content": "LONDON  Oct 5 Teva's blockbuster multiple sclerosis treatment Copaxone faces more generic competition in Europe  just two days after regulators approved cut-price copies of the medicine in the United States.",
        "date": "10052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's Copaxone faces more generic competition in Europe "
    },
    {
        "content": "Oct 4 Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while Teva shares plunged.",
        "date": "10042017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 4-Mylan surges  Teva slumps after FDA approves Copaxone copy "
    },
    {
        "content": "* Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate 40mg/ml and launch of generic Glatiramer Acetate 20mg/ml",
        "date": "10042017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva comments on anticipated at-risk U.S. Launch of generic Glatiramer Acetate "
    },
    {
        "content": "Oct 4 Shares of Mylan NV jumped about 17 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's copycat version of Teva Pharmaceutical Industries Ltd's blockbuster multiple sclerosis drug.",
        "date": "10042017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mylan surges as its generic of Teva's Copaxone gets FDA nod "
    },
    {
        "content": "* Teva Pharmaceutical Industries Ltd says Dan Suesskind appointed to co's board of directors Source text: (http://bit.ly/2wfjwNR) Further company coverage:",
        "date": "09252017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical Industries says Dan Suesskind appointed to co's board "
    },
    {
        "content": "LONDON Three banks have lined up \u20ac430m of leveraged loans to back private equity firm CVC Capital Partners\u2019 acquisition of the remaining assets in Teva Pharmaceutical Industries\u2019  women\u2019s health business  banking sources said.",
        "date": "09192017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "LPC: Banks line up \u20ac430m loan for CVC\u2019s Teva asset buy "
    },
    {
        "content": "LONDON  Sept 19 Three banks have lined up \u20ac430m of leveraged loans to back private equity firm CVC Capital Partners\u2019 acquisition of the remaining assets in Teva Pharmaceutical Industries\u2019  women\u2019s health business  banking sources said.",
        "date": "09192017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-LPC-Banks line up \u20ac430m loan for CVC\u2019s Teva asset buy "
    },
    {
        "content": "* Teva and Nuvelution Pharma partner to accelerate development of austedo\u00ae (deutetrabenazine) tablets for use in tourette syndrome in the united states",
        "date": "09192017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries Ltd   said on Monday it would sell the remaining assets in its specialty women's health business for $1.38 billion in two separate transactions.",
        "date": "09182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharma to sell more women's health assets for $1.38 billion "
    },
    {
        "content": "LONDON  Sept 19 Three banks have lined up around \u20ac430m of leveraged loans to back private equity firm CVC Capital Partners\u2019 acquisition of the remaining assets in Teva Pharmaceutical Industries\u2019  women\u2019s health business  banking sources said.",
        "date": "09192017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "LPC-Banks line up \u20ac430m loan for CVC\u2019s Teva asset buy "
    },
    {
        "content": "(The following statement was released by the rating agency) SINGAPORE/MUMBAI  September 19 (Fitch) Fitch Ratings has affirmed Singapore-based Jubilant Pharma Limited's (JPL) Long-Term Foreign-Currency Issuer Default Rating (IDR) at 'BB-'. The Outlook is Stable. The agency has also affirmed JPL's senior unsecured rating and the rating on its USD300 million 4.875% senior unsecured notes due 2021 at 'BB'. JPL's ratings reflect moderate linkages with parent  Jubilant Life Sciences Limited (JLS)  whi",
        "date": "09192017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Fitch Affirms Jubilant Pharma at 'BB-'; Outlook Stable "
    },
    {
        "content": "TEL AVIV  Sept 18 Teva Pharmaceutical Industries Ltd  said on Monday it would sell the remaining assets in its specialty women's health business for $1.38 billion in two separate transactions.",
        "date": "09182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva Pharma to sell more women's health assets for $1.38 bln "
    },
    {
        "content": "Sept 18 Teva Pharmaceutical Industries Ltd said on Monday it would sell some assets in its women's health business for $1.38 billion in two separate transactions.",
        "date": "09182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharma to sell some women's health assets for $1.38 bln "
    },
    {
        "content": "* Teva announces sale of remaining assets in specialty global women\u2019s health portfolio for $1.38 billion",
        "date": "09182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces sale of remaining assets in women\u2019s health portfolio for $1.38 bln "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd   is close to a deal to sell its women's health assets outside the United States to private equity firm CVC Capital Partners  the Fly reported  citing Bloomberg.",
        "date": "09132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva to sell women's health assets to CVC Capital Partners: report "
    },
    {
        "content": "Sept 13 Teva Pharmaceutical Industries Ltd is close to a deal to sell its women's health assets outside the United States to private equity firm CVC Capital Partners  the Fly reported  citing Bloomberg.",
        "date": "09132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to sell women's health assets to CVC Capital Partners - Report "
    },
    {
        "content": "* Teva receives fda priority review for first line use of trisenox\u00ae (arsenic trioxide) in patients with low to intermediate risk acute promyelocytic leukemia (apl)",
        "date": "09122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva receives FDA priority review for first line use of Trisenox "
    },
    {
        "content": "The S&P 500 surged over 1 percent to a record high close on Monday as tropical storm Irma caused less damage than expected in Florida  and after North Korea did not test-fire missiles over the weekend  which some had feared. |\u00a0Video ",
        "date": "09122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "S&P 500 chalks up record high as fear gives way "
    },
    {
        "content": "* Teva Pharmaceutical Industries Limited reports 5 percent stake in Wave Life Sciences Ltd as of Aug 30  2017 versus 9 percent stake as of Nov 16  2015 - SEC filing\u200d\u200b Source text: (http://bit.ly/2w4qQej) Further company coverage:",
        "date": "09052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva pharmaceutical reports 5 pct stake in Wave Life Sciences as of Aug 30  2017 versus 9 percent stake as of Nov 16  2015 "
    },
    {
        "content": "Teva Pharmaceutical Industries    on Monday agreed to sell its contraceptive brand Paragard to a unit of Cooper Cos  for $1.1 billion  on a day the struggling Israeli drugmaker named industry veteran Kare Schultz as CEO.",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva to sell contraceptive brand Paragard in $1.1 billion deal "
    },
    {
        "content": "Sept 11 Teva Pharmaceutical Industries   on Monday agreed to sell its contraceptive brand Paragard to a unit of Cooper Cos for $1.1 billion  on a day the struggling Israeli drugmaker named industry veteran Kare Schultz as CEO.",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva to sell contraceptive brand Paragard in $1.1 bln deal "
    },
    {
        "content": "Sept 11 Teva Pharmaceutical Industries   said it has agreed to sell Paragard  its intrauterine copper contraceptive brand  to a unit of Cooper Cos in a $1.1 billion cash deal.",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-UPDATE 1-Teva to sell contraceptive brand Paragard in $1.1 bln deal "
    },
    {
        "content": "Sept 11 Teva Pharmaceutical Industries   said it has agreed to sell Paragard  its intrauterine copper contraceptive brand  to a unit of Cooper Cos in a $1.1 billion cash deal.",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-Teva to sell its contraceptive brand Paragard in $1.1 bln deal "
    },
    {
        "content": "* The Cooper Companies announces definitive agreement to acquire Paragard\u00ae IUD from Teva",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Cooper Companies announces agreement to acquire Paragard\u00ae IUD from Teva "
    },
    {
        "content": "* Teva announces sale of Paragard\u00ae (intrauterine copper contraceptive) to CooperSurgical",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces sale of intrauterine contraceptive Paragard\u00ae to CooperSurgical "
    },
    {
        "content": "* Was head of Actavis  Ratiopharm (Adds details on Albrecht  succession of previous CEOs)",
        "date": "09012017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Bain  Cinven name industry veteran Albrecht as Stada CEO "
    },
    {
        "content": "JERUSALEM/COPENHAGEN Teva  poached Lundbeck's  Kare Schultz as its new chief executive on Monday  handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future. |\u00a0Video ",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Drugmaker Teva hires Lundbeck CEO Schultz to restore its health "
    },
    {
        "content": "* Teva shares up 16 pct in New York  Lundbeck falls 13 pct (Adds comments  details)",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Drugmaker Teva hires Lundbeck CEO Schultz to restore its health "
    },
    {
        "content": "* Teva Pharmaceutical Industries - in connection with being named co's president  CEO  K\u00e5re Schultz will receive annual base salary of U.S. $2 mln\u200d\u200b Source text for Eikon: (http://bit.ly/2gXT0Cu) Further company coverage:",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical Industries's CEO K\u00e5re Schultz will receive annual base salary of U.S.$2 mln\u200d\u200b "
    },
    {
        "content": "Sept 11 Incoming CEO of Teva Pharmaceutical Industries Kare Schultz made following comments to Reuters:",
        "date": "09112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Incoming Teva CEO says new strategy to address restructuring  debt "
    },
    {
        "content": "* Teva announces FDA approval of Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults Source text for Eikon: Further company coverage:",
        "date": "08302017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces FDA approval of Austedo tablets for treatment of tardive dyskinesia in adults "
    },
    {
        "content": "* Teva announces exclusive launch of generic Axiron\u00ae in the United States",
        "date": "08182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces exclusive launch of generic Axiron\u00ae in United States "
    },
    {
        "content": "* Speeding up divestment plans - sources (Adds context  TPG no comment)",
        "date": "08162017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "UPDATE 2-Israel's Teva seeks partners for new drugs to relieve pressure "
    },
    {
        "content": "JERUSALEM/LONDON/FRANKFURT Teva Pharmaceutical Industries   is looking to team up with other drugmakers to fund some of its development pipeline as it struggles with debts and expiring patents.",
        "date": "08162017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Israel's Teva seeks partners for new drugs to relieve pressure "
    },
    {
        "content": "JERUSALEM  Aug 16 Teva Pharmaceutical Industries said on Wednesday it was looking into a series of partnerships to fund some projects in its drug development pipeline  as the drugmaker seeks to pay down more than $5 billion of debt this year.",
        "date": "08162017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Israel's Teva seeks partners to fund some drug development "
    },
    {
        "content": "* Appaloosa LP dissolves class A share stake in Charter Communications Inc - sec filing",
        "date": "08142017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Appaloosa dissolves share stake in Teva Pharmaceutical  Goodyear Tire & Rubber "
    },
    {
        "content": "* Paulson & Co Inc cuts share stake in Teva Pharmaceutical Industries Ltd  by 38.7 percent to 6.7 million sponsored ADR - SEC filing",
        "date": "08142017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Paulson & Co cuts share stake in Teva Pharmaceutical  Sanofi "
    },
    {
        "content": "JERUSALEM Teva Pharmaceutical Industries   the world's largest generic drugmaker  said on Wednesday it was looking for a buyer for its Medis business as it sells assets to pare down its debt burden.",
        "date": "08092017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Drugmaker Teva looks to sell Medis business to help cut debt "
    },
    {
        "content": "* Teva announces FDA approval of QVAR redihaler (beclomethasone dipropionate HFA) inhalation aerosol",
        "date": "08072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces FDA approval of QVAR redihaler inhalation aerosol "
    },
    {
        "content": "JERUSALEM  Aug 9 Teva Pharmaceutical Industries   the world's largest generic drugmaker  said on Wednesday it was looking for a buyer for its Medis business as it sells assets to pare down its debt burden.",
        "date": "08092017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Drugmaker Teva looks to sell Medis business to help cut debt "
    },
    {
        "content": "JERUSALEM Teva Pharmaceutical Industries  said it was facing accelerating price erosion in the United States  hurting he Israeli drugmaker's profits and driving down its U.S. shares more than 20 percent.",
        "date": "08032017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva faces weakening prices in the U.S.  hurting profits "
    },
    {
        "content": "JERUSALEM  July 31 Teva Pharmaceutical Industries and South Korea's Celltrion said on Monday the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.",
        "date": "07312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. FDA to review Teva and Celltrion's cancer biosimilar drug "
    },
    {
        "content": "* Teva announces launch of generic Epiduo in the united states",
        "date": "07282017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces launch of generic Epiduo in the united states "
    },
    {
        "content": "* Teva says to take time over CEO appointment (Adds details from conference call  analyst quote)",
        "date": "08032017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Teva faces weakening prices in the U.S.  hurting profits "
    },
    {
        "content": "* CEO: Impact to Teva with at least one competitor to Copaxone 40 mg would be 20-25 cents/quarter to EPS",
        "date": "08032017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical management on Q2 results  CEO search "
    },
    {
        "content": "* Celltrion and Teva announce U.S. FDA acceptance of Biologics License Application for proposed biosimilar to Herceptin (trastuzumab)",
        "date": "07312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-U.S. FDA approves BLA for proposed biosimilar to Herceptin (trastuzumab) "
    },
    {
        "content": "* Teva pharmaceutical industries ltd - \u200d2017 business outlook revised to non-gaap eps of $4.30 - $4.50\u200b",
        "date": "08032017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Q2 non-gaap earnings per share $1.02 "
    },
    {
        "content": "JERUSALEM  Aug 3 Teva Pharmaceutical Industries said on Thursday it would continue to pursue a breach of contract suit against the former owners of its Rimsa plant in Mexico after a New York judge rejected Teva's claim of fraud.",
        "date": "08032017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to proceed with Rimsa breach of contract suit after ruling "
    },
    {
        "content": "* Teva announces the launch of generic vagifem in the United States",
        "date": "07242017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces launch of generic vagifem in U.S. "
    },
    {
        "content": "LONDON  July 21 AstraZeneca Chief Executive Pascal Soriot  responding to rumours he might leave the drugmaker to join rival Teva Pharmaceutical Industries   has told staff he expects to work \"together\" with employees to see the company succeed.",
        "date": "07212017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "AstraZeneca CEO reassures staff  aims to be at Sept cancer meet "
    },
    {
        "content": "TEL AVIV  July 23 Teva Pharmaceutical Industries said on Sunday it would lay off some of its 7 000 employees in Israel in the coming months as it reorganises in a drive to improve competitiveness.",
        "date": "07232017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharm to reduce workforce in Israel  mainly in production "
    },
    {
        "content": "LONDON  July 13 Shares in AstraZeneca fell more than 5 percent on Thursday after a media report said Chief Executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries.",
        "date": "07132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "AstraZeneca slumps on report CEO is heading to Teva "
    },
    {
        "content": "BRUSSELS  July 17 EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's blockbuster sleep disorder drug.",
        "date": "07172017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "EU regulators charge Teva over pay-for-delay drug deal "
    },
    {
        "content": "LONDON  July 13 Shares in AstraZeneca fell more than 5 percent on Thursday after the company declined to deny a media report that Chief Executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries .",
        "date": "07132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "REFILE-UPDATE 1-AstraZeneca slumps on report CEO is heading to Teva "
    },
    {
        "content": "BRUSSELS  July 17 EU antitrust regulators charged Israeli drugmaker Teva  on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug  putting it at risk of a fine.",
        "date": "07172017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-EU regulators charge Teva over pay-for-delay drug deal "
    },
    {
        "content": "* Said on Monday it does not believe it entered into \"any anti-competitive behavior\" with Cephalon.",
        "date": "07172017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharm denies anti-competitive behavior with Cephalon "
    },
    {
        "content": "TEL AVIV Israel-based Teva Pharmaceutical Industries  is expected to name Anglo-Swedish group AstraZeneca's  Chief Executive Pascal Soriot as Teva's next CEO  the Calcalist financial news website said on Wednesday.",
        "date": "07122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report "
    },
    {
        "content": "TEL AVIV  July 12 Israel-based Teva Pharmaceutical Industries is expected to name Anglo-Swedish group AstraZeneca's Chief Executive Pascal Soriot as Teva's next CEO  the Calcalist financial news website said on Wednesday.",
        "date": "07122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-AstraZeneca's CEO Soriot to join Israeli drugs company Teva-report "
    },
    {
        "content": "TEL AVIV  July 12 Israel-based Teva Pharmaceutical Industries will name AstraZeneca chief executive Pascal Soriot as its next CEO  the Calcalist financial news website said on Wednesday.",
        "date": "07122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "AstraZeneca's CEO Soriot to join Israeli drugs company Teva-report "
    },
    {
        "content": "Vivus Inc has reached an agreement allowing Teva Pharmaceuticals Ltd to launch a generic version of its anti-obesity drug Qsymia by December 2024  settling a patent lawsuit Vivus brought in New Jersey federal court.",
        "date": "07062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Vivus  Teva settle lawsuit over Teva's planned generic Qsymia "
    },
    {
        "content": "* Celltrion and teva announce u.s. Fda acceptance of biologics license application for proposed biosimilar to rituxan\u00ae (rituximab)",
        "date": "06292017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Celltrion and Teva announce FDA acceptance of BLA for CT-P10 "
    },
    {
        "content": "* Publication of AIM-TD study results in lancet psychiatry for investigational use of deutetrabenazine in tardive dyskinesia\u200b Source text for Eikon: Further company coverage:",
        "date": "06292017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva pharmaceutical publishes results of aim-td study in lancet psychiatry "
    },
    {
        "content": "* SAID ON SATURDAY WOCKHARDT LIMITED (INDIA) AND ITS SUBSIDIARIES SETTLE WITH TEVA AND ITS AFFILIATE A COMMERCIAL LITIGATION IN THE HIGH COURT  LONDON",
        "date": "06262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Wockhardt Bio AG says commercial litigation with Teva settled "
    },
    {
        "content": "* Says co  units settle with teva and its affiliate a commercial litigation in high court  london",
        "date": "06222017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Wockhardt  units settle commercial litigation with Teva Pharma  Cephalon "
    },
    {
        "content": "June 21 A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg  court documents showed.",
        "date": "06212017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "GSK wins $235 million from Teva in Coreg patent trial "
    },
    {
        "content": "* Mylan's letter to shareholders dated june 12 says Teva\u2019s expression of interest was simply not right for Mylan and its stakeholders",
        "date": "06132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Mylan says Teva's expression of interest was simply not right for Mylan and its stakeholders "
    },
    {
        "content": "TEL AVIV  June 21 Israel's biggest credit card company Isracard on Wednesday named Eyal Desheh  the outgoing chief financial officer of Teva Pharmaceutical Industries   as its new chairman.",
        "date": "06212017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Israeli credit card firm Isracard names outgoing Teva CFO as chairman "
    },
    {
        "content": "* Teva Pharmaceuticals USA Inc initiated a voluntary recall to retail-level for one lot of paliperidone extended-release tablets  3mg  90 count bottles",
        "date": "06152017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceuticals USA says recalls one lot of Paliperidone ER tablets "
    },
    {
        "content": "* Israel's Teva Pharmaceutical Industries is looking to refresh its board of directors with four new members as it tries to restore investor confidence after a series of missteps.",
        "date": "06112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharm looks to refresh board with four new nominees "
    },
    {
        "content": "* Teva announces launch of generic Zetia\u00ae in the United States",
        "date": "06122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical announces launch of generic Zetia in U.S. "
    },
    {
        "content": "JERUSALEM  June 7 Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraines cleared another late-stage study  setting it on course for U.S regulatory approval and launch in the second half of 2018.",
        "date": "06072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's migraine drug clears another hurdle  aims for launch in 2018 "
    },
    {
        "content": "* Teva announces exclusive launch of Generic Pataday\u00ae in the United States",
        "date": "06092017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces exclusive launch of Generic Pataday in the United States "
    },
    {
        "content": "* Mylan NV files proxy materials with U.S. SEC with co's letter  dated June 6  to Institutional Shareholder Services",
        "date": "06072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Mylan  in letter to proxy firm ISS  says Teva never made an offer to acquire Mylan "
    },
    {
        "content": "* Teva's fremanezumab meets all primary & secondary endpoints across both monthly and quarterly dosing regimens in phase iii study in episodic migraine prevention",
        "date": "06072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva's Fremanezumab meets all primary & secondary endpoints in phase III study in episodic migraine prevention "
    },
    {
        "content": "A federal appeals court has revived a California couple's lawsuit accusing Teva Pharmaceuticals USA of negligently failing to warn about the cancer risks of a drug that they say led to their son's death from lymphoma at the age of 21.",
        "date": "06052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "9th Circuit revives doctors' testimony in lawsuit against Teva Pharmaceuticals "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine cleared a late-stage study  paving the way for a U.S. regulatory submission later this year.",
        "date": "05312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva's migraine drug clears late-stage study "
    },
    {
        "content": "May 31 Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine cleared a late-stage study  paving the way for a U.S. regulatory submission later this year.",
        "date": "05312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva's migraine drug clears late-stage study "
    },
    {
        "content": "* Teva announces positive results for Phase III study of fremanezumab for the prevention of chronic migraine",
        "date": "05312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces positive results for Phase III study of fremanezumab for prevention of chronic migraine "
    },
    {
        "content": "May 31 Teva Pharmaceutical Industries Ltd said on Wednesday its experimental drug to prevent migraine met the main goal in a late-stage study.",
        "date": "05312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's migraine drug succeeds in late-stage study "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd has agreed to pay $1.6 million to resolve claims by two California counties that it and other drug companies engaged in deceptive marketing to play down the risks of prescription opioid painkillers.",
        "date": "05252017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva to pay $1.6 million to resolve California counties' opioid case "
    },
    {
        "content": "May 22 Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate  compared with Biogen Inc's Avonex  in a second late-stage trial  but failed to outperform Avonex in slowing disability progression rate.",
        "date": "05222017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Celgene MS drug clears key trial  but disability data falls short "
    },
    {
        "content": "* Teva takeda pharma to increase overseas production of generic medication to cut costs per year as drug prices continue to decline - Nikkei Source text (http://s.nikkei.com/2qOMEN4) Further company coverage:",
        "date": "05162017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Takeda Pharma to up overseas production of generic medication to cut costs - Nikkei "
    },
    {
        "content": "* Teva announces launch of generic Glumetza\u00ae in the United States",
        "date": "05152017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces launch of generic Glumetza in the U.S. "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries'  search for a new chief executive has resulted in the selection of a foreigner as the leading candidate  Israeli financial news website Calcalist said on Thursday.",
        "date": "05182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharmaceutical's search committee recommends foreign CEO: report "
    },
    {
        "content": "* Otsuka and Teva sign licensing agreement for Japan on prophylactic migraine drug candidate fremanezumab (TEV-48125)",
        "date": "05152017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Otsuka  Teva sign licensing agreement for Japan on TEV-48125 "
    },
    {
        "content": "TEL AVIV  May 18 Teva Pharmaceutical Industries' search for a new chief executive has resulted in the selection of a foreigner as the leading candidate  Israeli financial news website Calcalist said on Thursday.",
        "date": "05182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva Pharmaceutical's search committee recommends foreign CEO -report "
    },
    {
        "content": "TEL AVIV  May 18 Teva Pharmaceutical Industries' search for a new chief executive has resulted in the selection of a foreigner as the leading candidate  Israeli financial news website Calcalist said on Thursday.",
        "date": "05182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm search committee recommends foreigner for CEO -report "
    },
    {
        "content": "* Says a preclinical candidate calcitonin gene-related eptide (CGRP) antagonist  discovered by Heptares using its structure-based design approach in partnership with Teva Pharmaceutical Industries Ltd has triggered a $5 million payment from Teva to Heptares under the terms of their licensing and drug-discovery agreement signed in 2015",
        "date": "05182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF- Sosei Group unit Heptares to receive $5 million milestone "
    },
    {
        "content": "TEL AVIV Israel-based Teva Pharmaceutical Industries  reported a smaller-than-expected fall in first-quarter profit on Thursday  with sales boosted by its $40.5 billion acquisition last year of generics drug business Actavis.",
        "date": "05112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva first-quarter profit tops estimates  revenue up on Actavis deal "
    },
    {
        "content": "Botox-maker Allergan Plc  posted a first-quarter loss on Tuesday as it took a nearly $2 billion write-down on the value of its stake in Teva Pharmaceutical Industries   which has lost more than 40 percent of its value since last year.",
        "date": "05092017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Allergan posts loss as it writes down Teva holdings "
    },
    {
        "content": "* Increases Actavis synergy  cost benefit estimate by $200 mln",
        "date": "05112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva Q1 profit tops estimates  revenue up on Actavis deal "
    },
    {
        "content": "May 9 Botox-maker Allergan Plc posted a first-quarter loss on Tuesday as it took a nearly $2 billion write-down on the value of its stake in Teva Pharmaceutical Industries  which has lost more than 40 percent of its value since last year.",
        "date": "05092017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Allergan posts loss as it writes down Teva holdings "
    },
    {
        "content": "* Interim CEO: headcount reduced by 5 000 since Actavis deal  expects more cuts by end of 2017",
        "date": "05112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva interim CEO sees more headcount reductions "
    },
    {
        "content": "TEL AVIV  May 11 Teva Pharmaceutical Industries reported better-than- expected first-quarter profit as sales were boosted by its $40.5 billion acquisition of Allergan's Actavis generic drug business in August.",
        "date": "05112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm Q1 profit tops estimates  revenue rises "
    },
    {
        "content": "* Teva pharmaceutical industries ltd - qtrly non-gaap eps $1.06",
        "date": "05112017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva qtrly non-GAAP EPS $1.06 "
    },
    {
        "content": "TEL AVIV The chief financial officer of Teva Pharmaceutical Industries   Eyal Desheh  is stepping down and will likely be appointed chairman of Isracard  Bank Hapoalim's  credit card company  Israeli news websites reported on Tuesday.",
        "date": "04252017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharmaceutical CFO to step down: media "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair.",
        "date": "04202017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva's new asthma inhaler poses first competition for GSK's Advair "
    },
    {
        "content": "TEL AVIV  April 25 The chief financial officer of Teva Pharmaceutical Industries  Eyal Desheh  is stepping down and will likely be appointed chairman of Isracard  Bank Hapoalim's credit card company  Israeli news websites reported on Tuesday.",
        "date": "04252017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharmaceutical CFO to step down -media "
    },
    {
        "content": "April 20 Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair.",
        "date": "04202017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva's new asthma inhaler poses first competition for GSK's Advair "
    },
    {
        "content": "Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.",
        "date": "04262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Merck cholesterol drug Vytorin faces competition from Impax  Teva generics "
    },
    {
        "content": "TEL AVIV  April 25 Teva Pharmaceutical Industries hopes to resume some production at its newly purchased Mexican plant in the coming months  but an overhaul needed to bring the factory up to speed will take a few years  the company said on Tuesday.",
        "date": "04252017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva looks to resume some production at Rimsa plant in Mexico "
    },
    {
        "content": "April 20 Teva Pharmaceutical Industries Ltd launched its asthma inhaler and the authorized generic of the drug on Thursday  nearly three months after it got U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair.",
        "date": "04202017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva launches copy of asthma inhaler Advair "
    },
    {
        "content": "* Teva launches airduo\u2122 respiclick\u00ae and its authorized generic  two inhalers containing fluticasone propionate and salmeterol",
        "date": "04202017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical Industries expects that sales of authorized generic will represent most of sales of two products "
    },
    {
        "content": "April 26 Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.",
        "date": "04262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Merck cholesterol drug Vytorin faces competition from Impax  Teva generics "
    },
    {
        "content": "April 13 The U.S. Food and Drug Administration (FDA) has raised concerns over manufacturing controls at a Teva Pharmaceutical Industries plant in China  Israel's biggest company said in a regulatory filing on Thursday.",
        "date": "04132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. FDA raises concerns over Teva's plant in China "
    },
    {
        "content": "* Teva announces launch of generic vytorin\u00ae in the United States Source text for Eikon: Further company coverage:",
        "date": "04262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva reports launch of generic vytorin in United States "
    },
    {
        "content": "Eli Lilly and Co may move forward with a bid to have Dr. Reddy's Laboratories Ltd and Teva Pharmaceuticals held in contempt for violating a 12-year-old order blocking them from selling generic versions of antipsychotic drug Zyprexa  a U.S. judge has ruled.",
        "date": "04172017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Lilly may pursue contempt case against Dr. Reddy's  Teva - court "
    },
    {
        "content": "JERUSALEM  April 26 Teva Pharmaceutical Industries' finance chief Eyal Desheh will step down in the next few months after nearly a decade in the job  the second top official to resign from the Israel-based company this year.",
        "date": "04262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Finance chief quits drugmaker Teva  leaving another gap at top "
    },
    {
        "content": "* Teva Pharmaceutical Industries Ltd - on April 10  received a warning letter from the U.S. Food and Drug Administration (FDA) - SEC filing Source text for Eikon: (http://bit.ly/2o9jG5e) Further company coverage:",
        "date": "04132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceuticals received a warning letter from the U.S. FDA "
    },
    {
        "content": "* Content licence agreement with Teva Pharmaceutical Industries Ltd for Territory Of Israel Source text for Eikon: Further company coverage:",
        "date": "04262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Brain Resource announces content licence agreement with Teva Pharmaceutical Industries "
    },
    {
        "content": "April 3 Israel-based Teva Pharmaceutical Industries Ltd  said the U.S. Food and Drug Administration had approved its drug to treat chorea stemming from Huntington's disease  a fatal degenerative disorder.",
        "date": "04032017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva wins FDA approval for Huntington's drug "
    },
    {
        "content": "* Teva announces FDA approval of AUSTEDO\u2122 (deutetrabenazine) tablets for the treatment of chorea associated with huntington\u2019s disease",
        "date": "04032017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces FDA approval of AUSTEDO tablets for treatment of chorea associated with huntington\u2019s disease "
    },
    {
        "content": "JERUSALEM Teva Pharmaceutical Industries'  plans to end unprofitable activities and freeze recruitment  but said Israeli media reports of up to 6 000 layoffs were incorrect.",
        "date": "03232017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm says media reports of up to 6 000 layoffs incorrect "
    },
    {
        "content": "JERUSALEM  March 23 Teva Pharmaceutical Industries' plans to end unprofitable activities and freeze recruitment  but said Israeli media reports of up to 6 000 layoffs were incorrect.",
        "date": "03232017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva Pharm says media reports of up to 6 000 layoffs incorrect "
    },
    {
        "content": "JERUSALEM  March 23 Teva Pharmaceutical Industries may fire as many as 6 000 workers worldwide as part of a multi-year efficiency plan  Israel's Calcalist news website reported on Thursday.",
        "date": "03232017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm may fire 6 000 workers -Israeli media report "
    },
    {
        "content": "* OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico",
        "date": "03202017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico "
    },
    {
        "content": "* Teva Pharmaceutical Industries has agreed to sell a small stake in Israel-based Gamida Cell and in return will increase its holdings in Clal Biotechnology  the companies said on Sunday.",
        "date": "03052017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharm sells shares in Gamida Cell  raises stake in Clal Biotech "
    },
    {
        "content": "* Teva Pharmaceutical Industries Ltd - FDA has assigned a prescription drug user fee act (PDUFA) goal date of August 30  2017.",
        "date": "02282017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva says FDA granted priority review for SD-809 for treatment of tardive dyskinesia "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd has agreed to settle the \"vast majority\" of the roughly 4 000 lawsuits it faced over its generic version of the heartburn drug Reglan  which has been linked to a serious neurological disorder.",
        "date": "02172017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva settles 'vast majority' of lawsuits over generic Reglan "
    },
    {
        "content": "* Teva said to weigh options for branded generics to reduce debt - Bloomberg  citing sources",
        "date": "02132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva said to weigh options for branded generics to reduce debt- Bloomberg  citing sources "
    },
    {
        "content": "NEW YORK  Feb 13 Mick McGuire  founder of activist hedge fund Marcato Capital Management  told CNBC on Monday that Deckers Outdoor Corp had erred by investing significantly in physical retail stores.",
        "date": "02132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Marcato's McGuire criticizes Deckers' retail expansion -CNBC "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries  is seeking a new chief executive with deep drug industry experience  the Israel-based company said on Monday as it looks to restore confidence after a series of missteps and the departure of CEO Erez Vigodman.",
        "date": "02132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva seeks CEO with pharma background to lead recovery efforts "
    },
    {
        "content": "* Allergan CEO \"We have a good report card for 2016 and a positive outlook for 2017 and beyond\"",
        "date": "02082017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan says does not see U.S. tax reform in 2017 "
    },
    {
        "content": "* Shares in New York up 4 percent in early trade   (Recasts with comments about CEO  adds details from conference call  analyst)",
        "date": "02132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva seeks CEO with pharma background to lead recovery efforts "
    },
    {
        "content": "* Teva chairman: board has begun search for new CEO with extensive pharmaceutical experience",
        "date": "02132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva board seeks new CEO with extensive pharma experience "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries  was left without a permanent chief executive on Tuesday after Erez Vigodman stepped down  leaving new management to restore confidence in the world's biggest generic drugmaker after a series of missteps. |\u00a0Video ",
        "date": "02072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva CEO exits in ongoing crisis of confidence at drugmaker "
    },
    {
        "content": "Feb 6 Israel-based generic drugmaker Teva Pharmaceutical Industries Ltd said on Monday that Chief Executive Erez Vigodman was stepping down effective immediately and would be replaced on an interim basis by Yitzhak Peterburg  who has been chairman of Teva's board of directors.",
        "date": "02062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva names interim CEO  new chairman as Vigodman steps down "
    },
    {
        "content": "TEL AVIV  Feb 13 Teva Pharmaceutical Industries  reported better-than- expected fourth-quarter profit as sales were boosted by its $40.5 billion acquisition of Allergan's Actavis generic drug business on Aug. 2.",
        "date": "02132017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm Q4 profit  revenue beat expectations "
    },
    {
        "content": "* Investors call for major changes in the company   (Adds new investigation  investor comment)",
        "date": "02072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 5-Teva CEO exits in ongoing crisis of confidence at drugmaker "
    },
    {
        "content": "* Teva appoints Dr. Yitzhak Peterburg as interim chief executive officer  succeeding Erez Vigodman",
        "date": "02062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva appoints Dr. Yitzhak Peterburg as interim CEO "
    },
    {
        "content": "JERUSALEM  Feb 7 Teva Pharmaceutical Industries  said on Tuesday that Israeli authorities were investigating the same issues as an earlier U.S. bribery settlement.",
        "date": "02072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva says Israel probing same issues as U.S. bribery case "
    },
    {
        "content": "LONDON (Reuters Breakingviews) - U.S. President Donald Trump has criticised drugmakers for getting away with murder. Israeli group Teva  which has lost its second chief executive in four years  looks guiltier of self-harm.",
        "date": "02072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's new boss has bitter medicine to administer "
    },
    {
        "content": "* Shares have slumped in wake of patent setbacks  acquisitions",
        "date": "02072017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-UPDATE 2-Teva Pharm's CEO Vigodman steps down amid crisis of confidence "
    },
    {
        "content": "* Teva confirms generic Victoza patent challenge in the united states",
        "date": "02022017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva confirms generic Victoza patent challenge in the United States "
    },
    {
        "content": "* ISS Germany's Pharma Services will serve as Teva GmbH's new facility services provider",
        "date": "02012017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-ISS Germany wins contract with Teva Pharmaceuticals "
    },
    {
        "content": "A bitter defeat in a U.S. patents case sent shares in Teva Pharmaceutical Industries plummeting on Tuesday  the latest in a series of setbacks that has investors calling for major changes at the world's largest generic drugmaker.",
        "date": "01312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. court ruling on MS drug is the latest blow for Teva "
    },
    {
        "content": "LONDON Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair inhaler  although the real battle is still to come.",
        "date": "01302017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "As Teva wins U.S. approval for GSK Advair copy  main fight yet to come "
    },
    {
        "content": "LONDON  Jan 30 Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair inhaler  although the real battle is still to come.",
        "date": "01302017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "As Teva wins US approval for GSK Advair copy  main fight yet to come "
    },
    {
        "content": "* Teva announces FDA approval of two new RespiClick maintenance inhalers for the treatment of asthma  Source text for Eikon:  Further company coverage:",
        "date": "01302017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces FDA approval of two new RespiClick maintenance inhalers for the treatment of asthma "
    },
    {
        "content": "* Investors calling for major changes in the company   (Changes dateline  adds details  Mylan reaction  background)",
        "date": "01312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-U.S. court ruling on MS drug is the latest blow for Teva "
    },
    {
        "content": "* Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation  Source text for Eikon:  Further company coverage:",
        "date": "01312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation "
    },
    {
        "content": "* Teva confirms district court decision in Copaxone\u007f 40 mg/ml patent trial",
        "date": "01312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical confirms court decision in Copaxone 40 mg/ml patent trial "
    },
    {
        "content": "Jan 30 Teva Pharmaceutical Industries Ltd   said on Monday a U.S. court rejected four of the Israel-based drugmaker's claims of patent infringement on its top-selling multiple sclerosis treatment.",
        "date": "01312017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. court rejects Teva's patent-infringement claims on Copaxone "
    },
    {
        "content": "* Aralez Pharmaceuticals - on Jan 23 co  units  Pozen Inc filed lawsuit in U.S. District Court for Eastern district of Texas against Teva Pharmaceuticals",
        "date": "01272017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Aralez Pharmaceuticals  units  Pozen Inc filed lawsuit against Teva Pharmaceuticals "
    },
    {
        "content": "* Teva Pharmaceutical Industries Ltd - on January 26  Arie Belldegrun resigned as a member of the board of directors of teva pharmaceutical industries  Source text : (http://bit.ly/2jCFdkK) Further company coverage:",
        "date": "01262017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva pharmaceutical industries' Arie Belldegrun resigned as a member of the board "
    },
    {
        "content": "Jan 26 Teva Pharmaceutical Industries Ltd's  Barr Laboratories Inc has reached a $225 million settlement in an antitrust class action that accused the drugmaker of keeping a generic version of Bayer AG's  antibiotic Cipro off the market  court documents showed.",
        "date": "01272017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's Barr Labs settles Cipro antitrust case for $225 mln "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd's Barr Laboratories Inc has reached a $225 million settlement in an antitrust class action that accused the drugmaker of keeping a generic version of Bayer AG's antibiotic Cipro off the market  court documents showed.",
        "date": "01272017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's Barr Labs settles Cipro antitrust case for $225 million "
    },
    {
        "content": "* Teva receives FDA approval for VANTRELATM ER (hydrocodone bitartrate) extended-release tablets formulated with proprietary abuse deterrence technology  Source text for Eikon:  Further company coverage:",
        "date": "01182017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva receives FDA approval for VANTRELATM ER "
    },
    {
        "content": "A U.S. appeals court on Thursday said Eli Lilly and Co may block Teva Pharmaceutical Industries Ltd from selling a generic equivalent of its top-selling lung cancer drug Alimta  in a closely-watched patent case.",
        "date": "01122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Eli Lilly defeats Teva appeal over Alimta cancer drug "
    },
    {
        "content": "Jan 12 A U.S. appeals court on Thursday said Eli Lilly and Co may block Teva Pharmaceutical Industries Ltd from selling a generic equivalent of its top-selling lung cancer drug Alimta  in a closely-watched patent case.",
        "date": "01122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Eli Lilly defeats Teva appeal over Alimta cancer drug "
    },
    {
        "content": "Jan 12 A U.S. appeals court on Thursday ruled in favor of Eli Lilly & Co in a closely-watched patent case  saying a lower court judge correctly found Teva Pharmaceutical Industries Ltd and other companies liable for inducing the infringement of Lilly's lung cancer drug Alimta.",
        "date": "01122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva loses appeal against Eli Lilly in Alimta patent case "
    },
    {
        "content": "Jan 12 U.S. Appeals Court rules for Eli Lilly  and against Teva Pharmaceutical in Alimta patent case -- court ruling",
        "date": "01122017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd    the world's biggest generic drug maker  forecast 2017 revenue and profit below estimates  citing delays in new generic product launches.",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva's 2017 revenue  profit forecasts miss as launch delays weigh "
    },
    {
        "content": "* Sees 2017 non-GAAP net revenue $23.8 billion - $24.5 billion",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical Industries sees 2017 non-GAAP EPS $4.90 - $5.30 "
    },
    {
        "content": "* Sees mid-to-single digit pct price erosion in U.S. generics",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva's 2017 revenue  profit forecasts miss as launch delays weigh "
    },
    {
        "content": "Jan 6 Teva Pharmaceutical Industries Ltd   the world's biggest generic drug maker  forecast 2017 revenue and profit missing analysts' estimates.",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-UPDATE 1-Teva forecasts 2017 revenue  profit below estimates "
    },
    {
        "content": "Jan 6 Teva Pharmaceutical Industries Ltd   the world's biggest generic drug maker  forecast 2017 revenue and profit below analysts' estimates.",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-Teva forecasts 2017 revenue  profit below estimates "
    },
    {
        "content": "* Teva CEO: we continue to see challenges as a company and as an industry and we expect some of these challenges to continue in 2017: conf call",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva projects more than $750 mln in sales in U.S. product launches in 2017 "
    },
    {
        "content": "* Teva Exec:  we expect to see mid single-digit price erosion to continue in our base business in the United States: conf call",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva expects to see mid single-digit price erosion in U.S. "
    },
    {
        "content": "* Teva Pharmaceutical Industries Ltd - Copaxone 40 mg/ml is not expected to face generic competition in the United States during 2017",
        "date": "01062017",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva provides 2017 financial outlook "
    },
    {
        "content": "WASHINGTON Teva Pharmaceutical Industries  agreed to pay more than $519 million to settle U.S. criminal and civil allegations that the company bribed overseas officials to gain business for its medications  the U.S. Department of Justice said on Thursday.",
        "date": "12222016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva to pay U.S. government $519 million over foreign bribery charges "
    },
    {
        "content": "WASHINGTON Teva Pharmaceutical Industries agreed to pay more than $519 million to settle criminal and civil allegations that the company paid bribes to officials in Mexico  Ukraine and Russia to bolster sales of its pharmaceutical products  the U.S. Justice Department said in a press release Thursday.",
        "date": "12222016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva agrees to pay more than $519 million to settle bribe allegations: DoJ "
    },
    {
        "content": "JERUSALEM  Nov 28 Israel's Teva Pharmaceuticals  has partnered with Tel Aviv-based Syqe Medical to market in Israel medical cannabis for pain management that is administered with an inhaler.",
        "date": "11282016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm to market medical cannabis inhaler in Israel "
    },
    {
        "content": "* Aurobindo Pharma Ltd says Arrow Generiques to acquire select assets in France from Teva",
        "date": "11252016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Aurobindo Pharma unit Arrow Generiques to buy select assets in France from Teva "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries  on Tuesday lowered its full-year earnings forecast  citing launch delays for some drugs that have been pushed back by a year or so.",
        "date": "11152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva trims 2016 outlook on drug launch delays "
    },
    {
        "content": "* Cuts 2016 revenue outlook to $21.6-$21.9 bln from $22-$22.5 bln",
        "date": "11152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva trims 2016 outlook on drug launch delays "
    },
    {
        "content": "* Says cut 2016 outlook due to lower revenue from new drug launches which will now come in 2017 or 2018",
        "date": "11152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharm on 2016 outlook "
    },
    {
        "content": "TEL AVIV  Nov 15 Teva Pharmaceutical Industries  reported better than expected third-quarter profit as sales were boosted by its $40.5 billion acquisition of Allergan's generic drug business on Aug. 2.",
        "date": "11152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm Q3 beats estimates as acquisition lifts revenue "
    },
    {
        "content": "* Teva Pharmaceutical Industries Ltd - generic medicines revenues in q3 of 2016 were $2.9 billion  an increase of 32 pct compared to q3 of 2015",
        "date": "11152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical Industries Q3 gaap EPS $0.35 "
    },
    {
        "content": "* Announced appointment of David Stark to position of chief legal officer",
        "date": "11082016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical appoints David Stark as chief legal officer "
    },
    {
        "content": "* Teva Pharmaceutical Industries - approval of generic Tribenzor in U.S. and is in final stages of launch preparation",
        "date": "11072016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces approval of generic Tribenzor in the U.S. "
    },
    {
        "content": "* Teva Pharmaceuticals and IBM expand global partnership to enable drug development and chronic disease management with Watson  Source text for Eikon:  Further company coverage:    (Bangalore.newsroom@thomsonreuters.com)",
        "date": "10262016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceuticals and IBM expand global partnership "
    },
    {
        "content": "* Teva Pharmaceuticals and IBM expand global partnership to enable drug development and chronic disease management with Watson",
        "date": "10262016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva  IBM to enable drug development and chronic disease management with Watson "
    },
    {
        "content": "* Teva announces FDA acceptance of resubmitted new drug application for SD-809 for treatment of Chorea associated with Huntington disease",
        "date": "10202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva reports FDA acceptance of resubmitted NDA for SD-809 "
    },
    {
        "content": "Oct 17 Regeneron Pharmaceuticals Inc  and partner Teva Pharmaceutical Industries Ltd said the U.S. health regulator has placed a clinical hold on a mid-stage study of their experimental drug for chronic lower back pain.",
        "date": "10172016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "FDA places Regeneron and Teva's pain-drug study on hold "
    },
    {
        "content": "* On october 14  2016  received a warning letter from the U.S. Food and Drug Administration",
        "date": "10182016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceuticals receives warning letter from the FDA "
    },
    {
        "content": "* Regeneron and Teva provide update on fasinumab clinical development programs",
        "date": "10172016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Regeneron  Teva provide update on fasinumab clinical development programs "
    },
    {
        "content": "* Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars",
        "date": "10062016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva and Celltrion report exclusive biosimilar commercial partnership "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd  said on Wednesday it would sell Allergan Plc's  generics business in the UK and Ireland to India's Intas Pharmaceuticals Ltd  for 603 million pounds ($769.37 million).",
        "date": "10052016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva to sell Allergan's generics business in UK  Ireland for $769 million "
    },
    {
        "content": "Oct 5 Teva Pharmaceutical Industries Ltd  said on Wednesday it would sell Allergan Plc's  generics business in the UK and Ireland to India's Intas Pharmaceuticals Ltd for 603 million pounds ($769.37 million).",
        "date": "10052016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva to sell Allergan's generics business in UK  Ireland for $769 mln "
    },
    {
        "content": "Oct 5 Teva Pharmaceutical Industries Ltd  said on Wednesday it would sell Allergan Plc's  generics business in the UK and Ireland to India's Intas Pharmaceuticals Ltd for 603 million pounds ($769.37 million).",
        "date": "10052016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to sell Allergan's generics business in UK  Ireland for $769 mln "
    },
    {
        "content": "* Teva announces sale of UK and Ireland actavis assets and operations",
        "date": "10052016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces sale of UK and Ireland actavis assets and operations "
    },
    {
        "content": "* Teva announces launch of generic Beyaz\u007f in the United States  Source text for Eikon:  Further company coverage:",
        "date": "10122016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva launches generic Beyaz tablets in the U.S. "
    },
    {
        "content": "* Requests that their press release entitled \"Teva announces launch of generic Epzicom(reg) tablets in United States\" be killed",
        "date": "09282016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharma retracts press release on launch of generic Epzicom in U.S. "
    },
    {
        "content": "* Teva announces launch of generic epzicom tablets in the United States  Source text for Eikon:  Further company coverage:",
        "date": "09282016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva launches generic epzicom tablets in the U.S. "
    },
    {
        "content": "* Teva announces positive top-line data from second phase 3 study of SD-809 in Tardive Dyskinesia (TD)",
        "date": "09222016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces data from second phase 3 study of SD-809 "
    },
    {
        "content": "* To pay Regeneron $250 million upfront  share equally in global commercial value  ongoing research & development costs of about $1 billion",
        "date": "09202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva and regeneron announce global collaboration to develop Fasinumab "
    },
    {
        "content": "* Regeneron and Teva announce global collaboration to develop and commercialize Fasinumab  an investigational NGF antibody for chronic pain",
        "date": "09202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Regeneron  Teva collaborate to develop  commercialize Fasinumab "
    },
    {
        "content": "Sept 20 Regeneron Pharmaceuticals Inc  and Israeli drugmaker Teva Pharmaceutical Industries  on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.",
        "date": "09202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Regeneron  Teva take aim at Lilly/Pfizer pain drug "
    },
    {
        "content": "* Announces results from exploratory 52-week phase 2 PRIDE-HD study of pridopidine in Huntington disease",
        "date": "09192016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces results from exploratory 52-week phase 2 PRIDE-HD study of Pridopidine in Huntington disease "
    },
    {
        "content": "* Teva strengthens injectables portfolio with the launch of an authorized generic of Cubicin (Daptomycin for injection) in the United States  Source text for Eikon:  Further company coverage:",
        "date": "09152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva launches authorized generic of Cubicin in the U.S. "
    },
    {
        "content": "JERUSALEM  Sept 15 Teva Pharmaceutical Industries is collaborating with Intel Corp  to develop a wearable device and machine learning platform for Huntington disease patients  Teva said on Thursday.",
        "date": "09152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm  Intel to study Huntington disease progression "
    },
    {
        "content": "Sept 15 Teva Pharmaceutical Ltd Says It Will Deploy The Technology Platform In A Sub",
        "date": "09152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva collaborates with Intel to develop a device for use in huntington disease "
    },
    {
        "content": "Sept 9 Teva Pharmaceutical Industries Ltd  on Friday said it hopes to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's EpiPen device to treat severe allergic reactions  a move that could challenge the branded product's overwhelming dominance.",
        "date": "09092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva says hoping to launch EpiPen-like device by 2018 in U.S. "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd  said Friday it aims to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's  EpiPen device for treating severe allergic reactions  a move that would challenge the branded product's overwhelming market dominance.",
        "date": "09092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva says aims to launch EpiPen-like device by 2018 in U.S. "
    },
    {
        "content": "Sept 9 Teva Pharmaceutical Industries Ltd  said Friday it aims to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's EpiPen device for treating severe allergic reactions  a move that would challenge the branded product's overwhelming market dominance.",
        "date": "09092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Teva says aims to launch EpiPen-like device by 2018 in U.S. "
    },
    {
        "content": "NEW YORK Teva Pharmaceutical Industries  on Thursday lost a third patent for its top-selling multiple sclerosis treatment as U.S. patent officials ruled that Copaxone did not deserve legal protection  bringing rivals one step closer toward selling generic versions.",
        "date": "09012016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Third U.S. patent on Teva's MS drug Copaxone invalidated "
    },
    {
        "content": "* Mdxhealth and Teva pharmaceuticals sign distribution agreement for selectMDX in Israel  Source text for Eikon:  Further company coverage:",
        "date": "08312016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Mdxhealth and Teva sign distribution agreement for selectMDX in Israel "
    },
    {
        "content": "Mylan NV  said it would launch the first generic version of its allergy auto-injector EpiPen for $300  half the price of the branded product  the drugmaker's second step in less than a week to counter the backlash over the product's steep price. |\u00a0Video ",
        "date": "08292016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mylan to launch generic EpiPen at half the price of original "
    },
    {
        "content": "NEW YORK  Sept 1 Teva Pharmaceutical Industries  on Thursday lost a third patent for its top-selling multiple sclerosis treatment as U.S. patent officials ruled that Copaxone did not deserve legal protection  bringing rivals one step closer toward selling generic versions.",
        "date": "09012016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Third U.S. patent on Teva's MS drug Copaxone invalidated "
    },
    {
        "content": "* MDxHealth and Teva Pharmaceuticals sign distribution agreement for SelectMDx in Israel",
        "date": "08312016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-MDxHealth and Teva Pharmaceuticals sign distribution deal "
    },
    {
        "content": "* Launch raised as many questions as solutions-Democratic senator",
        "date": "08292016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 7-Mylan to launch generic EpiPen at half the price of original "
    },
    {
        "content": "* Moody's on Teva Pharmaceutical - there is no change to Teva Pharmaceutical Industries LTD Baa2 senior unsecured rating or stable outlook  Source text for Eikon:",
        "date": "08252016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Moody's says Teva's loss of two copaxone patents is credit negative "
    },
    {
        "content": "WASHINGTON Pharmaceutical company Mylan NV  has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office  which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were  after a review process  considered unpatentable.",
        "date": "08242016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Mylan wins round in fight with Teva over multiple sclerosis drug "
    },
    {
        "content": "WASHINGTON  Aug 24 Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office  which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were  after a review process  considered unpatentable.",
        "date": "08242016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Mylan wins round in fight with Teva over multiple sclerosis drug "
    },
    {
        "content": "WASHINGTON  Aug 24 Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office  which said on Wednesday that two patents for the multiple sclerosis drug Copaxone sold by Teva were  after a review process  considered unpatentable.",
        "date": "08242016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Mylan wins round in fight with Teva over multiple sclerosis drug "
    },
    {
        "content": "* Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone 40 mg",
        "date": "08242016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone "
    },
    {
        "content": "* Mylan invalidates two of Teva's Copaxone\u007f 40 mg/ml patents via U.S. Patent and Trademark Office's Inter Partes Review proceeding",
        "date": "08242016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Mylan invalidates two of Teva's Copaxone patents "
    },
    {
        "content": "* European Commission has granted marketing authorization for Cinqaero (reslizumab) in 28 countries of European Union  in addition to Norway",
        "date": "08182016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF- European Commission has granted Teva Pharmaceutical marketing authorization for cinqaero in 28 countries "
    },
    {
        "content": "* Reports a stake of 9.9 pct in Teva Pharmaceutical Industries Ltd as of July 27  2016 - SEC filing  Source text: (http://bit.ly/2aHghJE) Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "08082016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan Equico reports 9.9 pct stake in Teva Pharmaceutical "
    },
    {
        "content": "Aug 8 Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines  according to data from a mid-stage trial.",
        "date": "08082016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mesoblast cell treatment shows promise in rheumatoid arthritis -study "
    },
    {
        "content": "Aug 3 Allergan Plc said it would sell its Anda Inc distribution business to Israel's Teva Pharmaceutical Industries Ltd for $500 million  a day after Teva completed its $40.5 billion acquisition of the Dublin-based company's generics business.",
        "date": "08032016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Allergan to sell Anda drug distribution business to Teva "
    },
    {
        "content": "* Moody's on Teva - Moody's could upgrade ratings if Teva successfully integrates Allergan generics business and realizes significant synergies  Source text http://bit.ly/2azfyVV Further company coverage:",
        "date": "08022016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Moody's downgrades Teva's ratings to Baa2; outlook stable "
    },
    {
        "content": "WASHINGTON  Aug 4 A U.S. advisory panel on Thursday recommended approval of Egalet Corp's  long-acting opioid painkiller  Arymo ER  saying it dulls pain and could deter abuse by addicts seeking a quick high.",
        "date": "08042016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "UPDATE 1-U.S. panel backs approval of Egalet's abuse-resistant painkiller "
    },
    {
        "content": "* Allergan PLC completes divestiture of Global Generics Business to Teva Pharmaceuticals",
        "date": "08022016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan completes divestiture of global generics business to Teva Pharmaceuticals "
    },
    {
        "content": "JERUSALEM Teva Pharmaceutical Industries  will remain in the hunt for more acquisitions after completing a deal to buy Allergan's  generics business for $40.5 billion this week.",
        "date": "08042016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm eyes more acquisitions after buying Allergan's generics business "
    },
    {
        "content": "* For Q2 of 2016  Anda is expected to contribute approximately $375 million in net revenues excluding sales of Allergan's branded products",
        "date": "08032016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan announces sale of Anda distribution business to Teva "
    },
    {
        "content": "JERUSALEM  Aug 4 Teva Pharmaceutical Industries  will remain in the hunt for more acquisitions after completing a deal to buy Allergan's generics business for $40.5 billion this week.",
        "date": "08042016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva Pharm eyes more acquisitions after buying Allergan's generics business "
    },
    {
        "content": "* Teva Pharm CEO Erez Vigodman said on Thursday that any generic launch of the company's blockbuster multiple sclerosis drug Copaxone prior to court ruling  which is likely to come by the second half of 2018  \"would be at risk\".   Further company coverage:    (Reporting by Ari Rabinovitch and Steven Scheer)",
        "date": "08042016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharm CEO warns on launching generic Copaxone "
    },
    {
        "content": "WASHINGTON Teva Pharmaceutical Industries Ltd  won U.S. antitrust approval to purchase Allergan Plc's  generics business  after agreeing to divest 79 generic drugs to rival firms  the Federal Trade Commission said on Wednesday.",
        "date": "07272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva  Allergan win U.S. antitrust approval for generics deal "
    },
    {
        "content": "JERUSALEM  Aug 4 Teva Pharmaceutical Industries  will focus on the integration of Allergan's  generics business into its operations  it said on Thursday  after completing the $40.5 billion deal this week.",
        "date": "08042016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm to focus on integrating Allergan's generics business "
    },
    {
        "content": "Aug 4 Teva Pharmaceutical Industries Ltd Sees Revenues For 2016 To Be $22.0",
        "date": "08042016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Q2 non-GAAP earnings per share $1.25 "
    },
    {
        "content": "* Teva canada innovation announces approval of cinqair\u007f by health canada",
        "date": "07252016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Canada says Health Canada approved Cinqair "
    },
    {
        "content": "WASHINGTON  July 27 Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business  after agreeing to divest 79 generic drugs to rival firms  the Federal Trade Commission said on Wednesday.",
        "date": "07272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva  Allergan win U.S. antitrust approval for generics deal "
    },
    {
        "content": "WASHINGTON Teva Pharmaceutical Industries Ltd  won U.S. antitrust approval to purchase Allergan Plc's  generics business  after agreeing to divest more than 75 generic drugs to rival firms  the Federal Trade Commission said on Wednesday.",
        "date": "07272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva purchase of Allergan generics business gets OK with conditions "
    },
    {
        "content": "WASHINGTON  July 27 Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business  after agreeing to divest more than 75 generic drugs to rival firms  the Federal Trade Commission said on Wednesday.",
        "date": "07272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva purchase of Allergan generics business approved with conditions "
    },
    {
        "content": "* Teva receives clearance from the U.S. Federal Trade Commission for Actavis Generics acquisition",
        "date": "07272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva gets U.S. FTC clearance for Actavis Generics deal "
    },
    {
        "content": "* Fitch rates Teva Pharmaceutical's new EUR and CHF bonds 'BBB'  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "07222016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Fitch rates Teva Pharmaceutical's new EUR and CHF bonds 'BBB' "
    },
    {
        "content": "LONDON  July 27 Emerging market debt funds are enjoying a bumper inflow for the first time in three years  but portfolio managers are struggling to invest the bonanza as new bond sales have declined and trading volumes have evaporated.",
        "date": "07272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Sudden rush to emerging debt funds highlights scarcity of bonds "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  July 22 (Fitch) Fitch Ratings has assigned 'BBB' ratings to the EUR4  billion and CHF1 billion of new bonds issued by finance subsidiaries of Teva  Pharmaceutical Industries Ltd. (NYSE: TEVA; 'BBB'/Stable). Teva previously  issued $15 billion of USD-denominated bonds on July 18  2016. The approximately $20 billion of proceeds from the bond issuances  together with  up to $5 billion of expected draws on committed term loan facil",
        "date": "07222016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Fitch Rates Teva Pharmaceutical's New EUR and CHF Bonds 'BBB' "
    },
    {
        "content": "* Teva announces pricing of additional CHF1.0 billion of senior notes in connection with pending acquisition of actavis generics",
        "date": "07212016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva announces pricing of additional CHF1.0 billion of senior notes "
    },
    {
        "content": "* Fitch downgrades Teva Pharmaceuticals; rates new bonds 'BBB'",
        "date": "07202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Fitch downgrades Teva Pharmaceuticals; rates new bonds 'BBB' "
    },
    {
        "content": "TEL AVIV  July 19 Teva Pharmaceutical Industries Ltd said on Tuesday it successfully priced a debt offering for $15 billion worth of senior notes to help fund its acquisition of Allergan Plc's generic drug business.",
        "date": "07192016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharm prices $15 bln in notes to fund Allergan generics deal "
    },
    {
        "content": "NEW YORK  July 18 (IFR) - Teva Pharmaceutical looked likely to price its new six-part benchmark bond on Monday with negative concessions after generating a US$70bn book within hours of the announcement.",
        "date": "07182016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva ratchets in pricing on new benchmark bond "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries  will raise between $20 billion and $25 billion next week to finance its $40 billion acquisition of Allergan Plc's  generics business  the Globes financial news website said on Thursday.",
        "date": "07142016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharma to raise $20 billion to $25 billion in bond sale next week: report "
    },
    {
        "content": "NEW YORK  July 22 (IFR) - Teva Pharmaceutical raised more than US$20bn across three currencies this week via an acquisition-driven bond that took advantage of pent-up demand for corporate paper in a yield-starved market.",
        "date": "07222016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Investors scrap for Teva Pharmaceutical bonds "
    },
    {
        "content": "LONDON  July 21 (IFR) - Teva Pharmaceutical has set final price terms for a SFr1bn three-tranche bond issue to help fund its US$40.5bn acquisition of Actavis Generics  according to a lead bank.",
        "date": "07212016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "REFILE-Teva sets final price terms for SFr1bn bond deal "
    },
    {
        "content": "LONDON  July 20 Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.",
        "date": "07202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Your inhaler's watching you: drugmakers race for smart devices "
    },
    {
        "content": "LONDON  July 20 (IFR) - Teva Pharmaceutical has set final spreads for an expected \u007f4bn multi-tranche issue to help fund its US$40.5bn acquisition of Actavis Generics  according to a lead bank.",
        "date": "07202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva sets final terms for expected \u007f4bn M&A bond "
    },
    {
        "content": "* Announces pricing of $15 billion of senior notes in connection with pending acquisition of Actavis Generics",
        "date": "07192016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical announces pricing of $15 bln of senior notes "
    },
    {
        "content": "TEL AVIV  July 14 Teva Pharmaceutical Industries  will raise between $20 billion and $25 billion next week to finance its $40 billion acquisition of Allergan Plc's  generics business  the Globes financial news website said on Thursday.",
        "date": "07142016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva Pharm to raise $20-$25 bln in bond sale next week - report "
    },
    {
        "content": "LONDON  July 20 (IFR) - Teva Pharmaceutical has set guidance for a multi-tranche bond issue to help fund its US$40.5bn acquisition of Actavis Generics  according to a lead bank.",
        "date": "07202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva sets guidance for three tranche euro-denominated M&A bond "
    },
    {
        "content": "TEL AVIV  July 14 Teva Pharmaceutical Industries  will raise between $20 billion and $25 billion next week to finance its $40 billion acquisition of Allergan Plc's  generics business  the Globes financial news website reported on Thursday.",
        "date": "07142016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm to raise $20-$25 bln in bond sale next week -report "
    },
    {
        "content": "* S&P - Teva pharmaceutical industries ltd. ratings lowered to 'BBB' from 'BBB+'; outlook stable",
        "date": "07132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-S&P - Teva Pharmaceutical Industries Ltd ratings lowered to 'BBB' from 'BBB+'; outlook stable "
    },
    {
        "content": "July 12 Teva Pharmaceutical Industries Ltd   the world's biggest generic drugmaker  raised its adjusted profit and revenue estimates for the second quarter  sending its shares up 2 percent in after-hours trading.",
        "date": "07122016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva raises second-quarter estimates "
    },
    {
        "content": "NEW YORK/TEL AVIV Teva Pharmaceutical Industries Ltd  said on Wednesday it expected its $40 billion deal to buy Allergan Plc's  generics business to close \"at any time \" even as the companies extended the deadline for completing the transaction to October to allow more time for the U.S. antitrust review.",
        "date": "07132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva says Allergan deal to close 'any time'  expects U.S. antitrust clearance "
    },
    {
        "content": "* Sees non-GAAP EPS for second quarter is now expected to be $1.19 - $1.22",
        "date": "07122016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical expects Q2 revenue to be $4.9 bln-$5.0 bln "
    },
    {
        "content": "NEW YORK/TEL AVIV  July 13 Teva Pharmaceutical Industries Ltd said on Wednesday it expected its $40 billion deal to buy Allergan Plc's generics business to close \"at any time \" even as the companies extended the deadline for completing the transaction to October to allow more time for the U.S. antitrust review.",
        "date": "07132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Teva says Allergan deal to close 'any time'  expects U.S. antitrust clearance "
    },
    {
        "content": "July 13 Allergan Plc said it extended the deadline to close a deal to sell its generic business to Teva Pharmaceutical Industries Ltd by three months to October.",
        "date": "07132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-Allergan extends Teva deal deadline "
    },
    {
        "content": "* Allergan  Teva deal approval expected in next 2 weeks - CNBC citing sources   Further company coverage: [AGN.N TEVA.TA]   (Bengaluru Newsroom: +1 646 223 8780)",
        "date": "07132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan  Teva deal approval expected in next 2 weeks - CNBC "
    },
    {
        "content": "* Sees 2016 revenue $22.0-$22.5 bln  non-gaap EPS $5.20-$5.40",
        "date": "07132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Israel's Teva Pharm provides 2016-2019 financial estimates "
    },
    {
        "content": "* Co and teva pharmaceutical industries ltd entered into an amendment  dated july 11  2016 to master purchase agreement",
        "date": "07132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan  Teva entered amendment to master purchase agreement "
    },
    {
        "content": "* Prasco Laboratories says entered into agreements with Teva Pharmaceutical Industries Ltd. (Teva) and Shire LLC  an indirect subsidiary of Shire Plc",
        "date": "06282016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Prasco acquires Teva's generic of Adderall XR extended release capsules  CII "
    },
    {
        "content": "Australia's Mayne Pharma Group Ltd  on Tuesday said it will acquire U.S. generic products from Teva Pharmaceuticals  for $652 million  helping it propel into the top 2 in the general oral contraceptives market in the United States.",
        "date": "06272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Mayne Pharma nears deal for Teva assets: source "
    },
    {
        "content": "* Final decision by European Commission is expected in second half of 2016",
        "date": "06242016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical gets CHMP positive opinion for Cinqaero\u007f "
    },
    {
        "content": "June 27 Australia's Mayne Pharma Group Ltd  on Tuesday said it will acquire U.S. generic products from Teva Pharmaceuticals for $652 million  helping it propel into the top 2 in the general oral contraceptives market in the United States.",
        "date": "06272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Mayne Pharma nears deal for Teva assets -source "
    },
    {
        "content": "June 27 Australian pharmaceutical company Mayne Pharma Group Ltd is nearing a deal to purchase assets from Teva Pharmaceuticals worth around $600 million  a person familiar with the matter said on Monday.",
        "date": "06272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mayne Pharma nears deal for Teva assets -source "
    },
    {
        "content": "* Teva and Antares Pharma announce launch of Generic Imitrex\u007f in the United States  Source text for Eikon:  Further company coverage:",
        "date": "06272016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva and Antares Pharma announce launch of Generic Imitrex\u007f in the U.S. "
    },
    {
        "content": "Impax Laboratories Inc  said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd  and Allergan Plc  for about $586 million.",
        "date": "06212016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Impax buys generic drugs from Teva  Allergan for $586 million "
    },
    {
        "content": "* Expects 2016 total company revenues to increase at least 15% over full year 2015",
        "date": "06212016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Impax signs agreements to acquire generic products from Teva  Allergan "
    },
    {
        "content": "June 21 Impax Laboratories Inc said it would buy a portfolio of generic products from Teva Pharmaceutical Industries Ltd and Allergan Plc  for about $586 million.",
        "date": "06212016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Impax buys portfolio of generic products from Teva  Allergan "
    },
    {
        "content": "* Sagent Pharmaceuticals acquires product portfolio from Teva Pharmaceutical Industries Ltd",
        "date": "06162016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Sagent Pharmaceuticals buys product portfolio from Teva Pharmaceutical "
    },
    {
        "content": "* Mesoblast shares plummet 42 pct to lows not seen since 2009",
        "date": "06142016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "UPDATE 1-Mesoblast shares slump to 2009 low as Teva ends partnership "
    },
    {
        "content": "June 13 Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure  which is currently in late stage testing  from Teva Pharmaceutical Industries.",
        "date": "06132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mesoblast regains full rights to stem cell heart failure treatment "
    },
    {
        "content": "June 13 The following bids  mergers  acquisitions and disposals were reported by 1330 GMT on Monday:",
        "date": "06132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "* Teva announces voluntary suspension of marketing for Zecuity in US",
        "date": "06132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva suspends marketing for Zecuity in US "
    },
    {
        "content": "MUMBAI India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.",
        "date": "06112016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "India's Dr Reddy's in $350 million deal to buy eight U.S. drugs from Teva  Allergan "
    },
    {
        "content": "* Expect court will enter order enjoining defendants from launching their respective generic versions of treanda until patent expiry in 2026",
        "date": "06102016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical announces favorable court ruling in TREANDA patent infringement litigation "
    },
    {
        "content": "To access the newsletter  click on the link:    http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_06132016.pdf               FACTORS TO WATCH     4:30 pm: RBI Deputy Governor S.S.Mundra at a book launch event in Mumbai.     5:30 pm: Government to release May consumer price inflation data in New Delhi.          GMF ASIA LIVECHAT - MARKETS FOCUS with Jim Rogers  Chairman  Rogers Holdings and Beeland Interests The Global Markets Forum welcomes back businessman  investor and aut",
        "date": "06132016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Morning News Call - India  June 13 "
    },
    {
        "content": "MUMBAI  June 11 India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries  and Allergan Plc for $350 million in cash to bolster its U.S. business.",
        "date": "06112016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-UPDATE 1-India's Dr Reddy's in $350 mln deal to buy 8 U.S. drugs from Teva  Allergan "
    },
    {
        "content": "* U.S. FDA Advisory Panel supports approval of Teva's long acting opioid painkiller  Vantrela ER",
        "date": "06072016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-U.S. FDA advisory panel backs Teva's abuse-resistant opioid painkiller "
    },
    {
        "content": "MUMBAI  June 11 India's No. 2 drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy a portfolio of eight generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for $350 million in cash to bolster its U.S. business.",
        "date": "06112016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-India's Dr Reddy's to buy 8 U.S. generic drugs from Teva  Allergan for $350 mln "
    },
    {
        "content": "June 7 A U.S. advisory panel recommended approving Teva Pharmaceutical Industries Ltd's   long-acting opioid painkiller  Vantrela ER  saying data showed it has some abuse-resistant properties.",
        "date": "06072016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-FDA panel backs Teva's abuse-resistant opioid painkiller "
    },
    {
        "content": "JERUSALEM Approval for Israel-based Teva Pharmaceutical Industries' drug to treat the neurological disorder chorea has been held up by U.S. regulators seeking further blood studies  the company said on Tuesday.",
        "date": "05312016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "FDA asks Teva Pharmaceutical for further study on Huntington's drug "
    },
    {
        "content": "JERUSALEM  May 31 Approval for Israel-based Teva Pharmaceutical Industries' drug to treat the neurological disorder chorea has been held up by U.S. regulators seeking further blood studies  the company said on Tuesday.",
        "date": "05312016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-FDA asks Teva Pharmaceutical for further study on Huntington's drug "
    },
    {
        "content": "JERUSALEM  May 31 Israel-based Teva Pharmaceutical Industries said on Tuesday approval for a drug to treat chorea stemming from Huntington disease (HD) has been held up by U.S. regulators seeking further blood study.",
        "date": "05312016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "FDA asks Teva Pharmaceutical for further study on Huntington drug "
    },
    {
        "content": "* FDA has asked Teva to examine blood levels of certain metabolites",
        "date": "05312016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical receives complete response letter for SD-809 "
    },
    {
        "content": "* Unit  teva pharmaceuticals usa  inc.  Entered into settlement agreement to resolve patent litigation relating to Folotyn",
        "date": "05252016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Spectrum Pharma says unit  Teva enter settlement agreement "
    },
    {
        "content": "NEW YORK Allergan Plc  Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd  in a matter of weeks  opening the door for new acquisitions.",
        "date": "05232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Allergan CEO says company is 'weeks away' from closing Teva deal "
    },
    {
        "content": "NEW YORK  May 23 Allergan Plc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks  opening the door for new acquisitions.",
        "date": "05232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Allergan CEO says company is \"weeks away\" from closing Teva deal "
    },
    {
        "content": "May 23 Allergan Inc Chief Executive Brent Saunders said on Monday the company expects to close the $40.5 billion sale of its generic medicines portfolio to Teva Pharmaceutical Industries Ltd in a matter of weeks  opening the door for new acquisitions.",
        "date": "05232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Allergan CEO says company is \"weeks away\" from closing Teva deal "
    },
    {
        "content": "* Allergan CEO says company is free to do multibillion dollar deals after Teva transaction closes",
        "date": "05232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan CEO says company is \"weeks away\" from closing Teva deal "
    },
    {
        "content": "* Says in analyst conference call that new Vraylar schizophrenia drug has blockbuster sales potential",
        "date": "05102016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan says to pay down $8 bln in debt with Teva-deal proceeds "
    },
    {
        "content": "* Company expects to execute $4 - $5 billion in open market repurchases",
        "date": "05102016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Allergan announces share repurchase program of up to $10 bln "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries'   the world's biggest generic drugmaker  reported better-than-expected first-quarter profits on Monday and said it still expected its $40.5 billion acquisition of Allergan's  generic drug business to close in June.",
        "date": "05092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharm's quarterly profit beats forecast  sees Actavis deal closing in June "
    },
    {
        "content": "TEL AVIV  May 9 Teva Pharmaceutical Industries'   the world's biggest generic drugmaker  reported better-than-expected first-quarter profits on Monday and said it still expected its $40.5 billion acquisition of Allergan's  generic drug business to close in June.",
        "date": "05092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva Pharm's quarterly profit beats forecast  sees Actavis deal closing in June "
    },
    {
        "content": "* Teva Pharmaceutical Industries Ltd says generic medicines revenues in q1 of 2016 amounted to $2.2 billion  a decrease of 17%",
        "date": "05092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical's Q1 Non-GAAP EPS $1.20 "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd is finalizing as much as $2 billion in asset sale agreements to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan Plc's generic drug portfolio  according to a source familiar with the matter.",
        "date": "05052016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharm finalizing asset sales to clear Allergan deal: source "
    },
    {
        "content": " ",
        "date": "05092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "A "
    },
    {
        "content": "May 5 Teva Pharmaceutical Industries Ltd  is finalizing as much as $2 billion in asset sale agreements to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan Plc's generic drug portfolio  according to a source familiar with the matter.",
        "date": "05052016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm finalizing asset sales to clear Allergan deal -source "
    },
    {
        "content": "TEL AVIV  May 9 Teva Pharmaceutical Industries  reported a smaller than expected decline in first-quarter profit as sales of generic drugs fell 17 percent while revenue from its top drug Copaxone rose.",
        "date": "05092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm Q1 profit falls less than expected "
    },
    {
        "content": "* Teva announces fda approval of proair respiclick\u007f (albuterol sulfate) inhalation powder for pediatric asthma patients ages 4 to 11",
        "date": "04292016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva says FDA has approved ProAir RespiClick "
    },
    {
        "content": "* Fitch maintains Teva Pharmaceuticals' ratings on negative watch",
        "date": "04202016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Fitch maintains Teva Pharmaceuticals' ratings on negative watch "
    },
    {
        "content": "Teva Pharmaceuticals and Target Corp have asked the U.S. Supreme Court to overturn an Illinois appeals court decision they say conflicts with its own rulings that hold generic drugmakers cannot be liable solely for keeping an allegedly dangerous product on the market.",
        "date": "04112016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Case to Watch: Teva  Target ask SCOTUS to squash Illinois preemption ruling "
    },
    {
        "content": "March 31 Israel's Teva Pharmaceutical Industries Ltd and Japan's Takeda Pharmaceutical Co Ltd  named Hiroshi Matsumori on Thursday as the chief executive of their new joint venture in Japan.",
        "date": "04012016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva and Takeda name pharma veteran as CEO of Japan joint venture "
    },
    {
        "content": "* Teva announces FDA approval of Cinqair\u007f (reslizumab) injection",
        "date": "03232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharmaceutical Industries Ltd announces FDA approval of Cinqair injection "
    },
    {
        "content": "The U.S. Food and Drug Administration said on Wednesday it had approved Teva Pharmaceutical Industries Ltd's drug to treat asthma in adults who have a history of severe attacks despite taking medication.",
        "date": "03232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. FDA approves Teva's biotech drug for severe asthma "
    },
    {
        "content": "March 23 The U.S. Food and Drug Administration said on Wednesday it had approved Teva Pharmaceutical Industries Ltd's  drug to treat asthma in adults who have a history of severe attacks despite taking medication.",
        "date": "03232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-U.S. FDA approves Teva's biotech drug for severe asthma "
    },
    {
        "content": "March 23 The U.S. Food and Drug Administration said on Wednesday it had approved Teva Pharmaceutical Industries Ltd's  drug to treat asthma in adults who have a history of severe attacks despite taking medication.",
        "date": "03232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. FDA approves Teva's treatment for asthma "
    },
    {
        "content": "LONDON  March 16 (IFR) - Anheuser-Busch InBev has opened books on a minimum \u007f6bn six-part bond to help fund a portion of its acquisition of rival SABMiller  a test of European investor demand for jumbo M&A financings.",
        "date": "03162016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-AB InBev prepares jumbo euro bond "
    },
    {
        "content": "TEL AVIV  March 15 Israel-based Teva Pharmaceutical Industries said on Tuesday it now expects its $40.5 billion acquisition of the generic drug activities of Allergan to be completed by June.",
        "date": "03152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm sees close of $40.5 bln Allergan generics deal by June "
    },
    {
        "content": "TEL AVIV Israel-based Teva Pharmaceutical Industries  said on Tuesday it now expects its $40.5 billion acquisition of the generic drug activities of Allergan  to be completed by June.",
        "date": "03152016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm sees close of $40.5 billion Allergan generics deal by June "
    },
    {
        "content": "BRUSSELS  March 10 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "03102016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "UPDATE 1-EU mergers and takeovers (March 10) "
    },
    {
        "content": "BRUSSELS  March 10 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "03102016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "EU mergers and takeovers (March 10) "
    },
    {
        "content": "BRUSSELS  March 10 The European Commission on Thursday approved Teva Pharmaceutical Industries'  $40.5 billion acquisition of the generics activities of Allergan  conditional on a number of divestments  notably Allergan businesses in Britain and Ireland.",
        "date": "03102016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "EU approves Teva bid for Allergan's generics with conditions "
    },
    {
        "content": "LONDON  March 10 (IFR) - Teva expects to win EU antitrust approval for its US$40.5bn acquisition of Allergan  paving the way for a jumbo US$22bn multi-currency bond issue in the second quarter of 2016  several sources told IFR.",
        "date": "03102016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva acquisition inches closer  and so do bonds "
    },
    {
        "content": "BRUSSELS  March 9 Teva Pharmaceutical Industries  is expected to win EU antitrust approval for its $40.5 billion bid for Allergan's generics unit after agreeing to sell off some of its products to appease regulators  three people familiar with the matter said on Wednesday.",
        "date": "03092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "EXCLUSIVE-Teva set to win EU okay for $40.5 bln Allergan deal -sources "
    },
    {
        "content": "BRUSSELS Teva Pharmaceutical Industries  is expected to win EU antitrust approval for its $40.5 billion bid for Allergan's  generics unit after agreeing to sell off some of its products to appease regulators  three people familiar with the matter said on Wednesday.",
        "date": "03092016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Exclusive: Teva set to win EU okay for $40.5 billion Allergan deal - sources "
    },
    {
        "content": "NEW YORK  March 3 Calls in the U.S. presidential campaign to cut pharmaceutical prices are not helping to revive a barely two-month-old exchange-traded fund that invests in shares of generic drugmakers.",
        "date": "03032016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Generic drug ETF ailing despite political focus on high drug prices "
    },
    {
        "content": "A whistleblower lawsuit accusing Teva Pharmaceuticals of using a sham educational speakers program to pay kickbacks to doctors for prescribing its Parkinson's disease and multiple sclerosis drugs can go forward  a Manhattan federal judge has ruled.",
        "date": "02232016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Judge lets whistleblower case over Teva speaker program proceed "
    },
    {
        "content": "BRUSSELS Teva Pharmaceutical Industries Ltd  has offered concessions to allay EU antitrust concerns over its $40.5 billion bid for Allergan's  generics unit which will cement its position as the world's largest generics drugmaker.",
        "date": "02192016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva offers EU concessions over Allergan generics deal "
    },
    {
        "content": "* Deal would cement Teva as world's largest generics drugmaker",
        "date": "02192016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva offers EU concessions over Allergan generics deal "
    },
    {
        "content": "BRUSSELS  Feb 19 Teva Pharmaceutical Industries Ltd has offered concessions to allay antitrust concerns over its $40.5 billion bid for Allergan's  generics unit  European Union regulators said on Friday.",
        "date": "02192016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva offers EU concessions over Allergan generics deal - EU "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries   the world's largest generics drugmaker  reported a fall in fourth-quarter profit and revenue on lower sales of its top drug and said it expects to close its purchase of Actavis by early April.    Israel-based Teva  agreed last year to buy Allergan's  Actavis generic business for $40.5 billion as well as Mexico's Rimsa for $2.3 billion.",
        "date": "02112016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva says Actavis deal to close by April as profit falls "
    },
    {
        "content": "* Sees Q1 adjusted EPS $1.32-$1.36  revenue $4.7-$4.9 bln   (Adds Teva comments  details from conference call)",
        "date": "02112016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva says Actavis deal to close by April as profit falls "
    },
    {
        "content": "TEL AVIV  Feb 11 Teva Pharmaceutical Industries   the world's largest generics drugmaker  reported a decline in fourth-quarter profit and revenue as sales of its top drug Copaxone fell in the wake of competition.",
        "date": "02112016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm Q4 profit  revenue fall as Copaxone sales drop "
    },
    {
        "content": "JERUSALEM  Jan 4 Teva Pharmaceutical Industries  and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials  citing the occurrence of non-fatal cardiovascular events in eight patients.",
        "date": "01042016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva  Active Biotech halt higher doses of oral MS drug in trials "
    },
    {
        "content": "An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's <TEVA.TA) experimental drug reslizumab for severe asthma in patients aged 18 and older.",
        "date": "12092015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "U.S. FDA advisers recommend approval of Teva asthma drug for adults "
    },
    {
        "content": "Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.",
        "date": "12082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva gets FDA approval for cancer drug "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd  is in the process of divesting about $1 billion worth of assets to address antitrust concerns over its deal to buy Allergan Plc's  generic drugs business  people familiar with the matter said.",
        "date": "12032015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva divesting $1 billion in assets to clear Allergan deal "
    },
    {
        "content": "Dec 3 Teva Pharmaceutical Industries Ltd  is in the process of divesting about $1 billion worth of assets to address antitrust concerns over its deal to buy Allergan Plc's generic drugs business  people familiar with the matter said.",
        "date": "12032015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva divesting $1 bln in assets to clear Allergan deal -sources "
    },
    {
        "content": "JERUSALEM  Nov 30 Israel's Teva Pharmaceutical  has agreed a deal with Osaka-based Takeda to bring its portfolio of generic drugs to Japan  where a rapidly aging population is in need of affordable medications.",
        "date": "11302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva to partner with Takeda to bring generic drugs to Japan "
    },
    {
        "content": "* \"pen 1\" development project with teva pharmaceutical relates to a generic form of forteo marketed by eli lilly",
        "date": "04052016",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Antares says partner Teva first to file for generic version of Lilly's Forteo "
    },
    {
        "content": "Nov 4 Drugmakers AstraZeneca Plc   and Cephalon  a unit of Teva Pharmaceutical Industries Ltd    reached a multistate accord on Wednesday over civil charges they overbilled state Medicaid programs  the New York Attorney General announced.",
        "date": "11042015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "AstraZeneca  Teva reach deal with states in Medicaid pricing case "
    },
    {
        "content": "Nov 4 Drugmakers AstraZeneca Plc   and Cephalon  a unit of Teva Pharmaceutical Industries Ltd    reached a multistate accord on Wednesday over civil charges they overbilled state Medicaid programs  the New York Attorney General announced.",
        "date": "11042015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-AstraZeneca  Teva reach deal with states in Medicaid pricing case "
    },
    {
        "content": "LOS ANGELES Express Scripts Holding Co  the largest U.S. pharmacy benefit manager  is reviewing pharmacy programs run by AbbVie Inc and Teva Pharmaceuticals Industries Ltd after finding questionable practices at Valeant Pharmaceuticals International Inc's partner pharmacy  Philidor Rx Services.",
        "date": "10302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Beyond Valeant  U.S. payers scrutinize other drugmaker ties to pharmacies "
    },
    {
        "content": "Oct 30 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies  including Solarcity  Nvidia and LinkedIn Corp  on Friday.           HIGHLIGHTS     * LinkedIn : Barclays  Mizuho  RBC  others raise target price on the stock     * Oceaneering Intl Inc : Cowen and Company cuts to market perform from outperform       * Solarcity : Goldman Sachs  Baird downgrade the stock     * Makemytrip Ltd : Deutsche Bank cuts to hold from buy      * Drea",
        "date": "10302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. RESEARCH ROUNDUP-LinkedIn  Nvidia  Dreamworks Animation "
    },
    {
        "content": "* Plans to raise $7 billion in equity  $22 billion in bonds   (Recasts with Allergan financing  share reaction)",
        "date": "10292015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva Pharmaceutical sets out Actavis funding after strong earnings update "
    },
    {
        "content": "* CEO: Impact from generic competition in 40 mg Copaxone estimated at $1.2 billion revenue  $0.65 EPS in 2017",
        "date": "10292015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva to raise $7 bln equity  plans $22 bln bond to fund Actavis deal "
    },
    {
        "content": "JERUSALEM  Oct 29 Teva Pharmaceutical Industries   the world's largest generics drugmaker  reported third-quarter profit that beat estimates and raised its full-year 2015 outlook.",
        "date": "10292015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharmaceutical profit beats estimates  raises 2015 outlook "
    },
    {
        "content": "* Active Biotech's partner Teva presents data on Laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS congress  Source text for Eikon:  Further company coverage:    (Stockholm Newsroom)",
        "date": "10062015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-Active Biotech says partner Teva to present data on laquinimod at ECTRIMS congress this week "
    },
    {
        "content": "Drugmaker Allergan Plc  said it expected revenue to be greater than $8 billion in the second half as it completes the sale of its generics business to Teva Pharmaceuticals Industries Ltd  .",
        "date": "09282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Allergan forecasts second-half revenue above $8 billion "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries has struck a deal to buy Mexican drugmaker Representaciones e Investigaciones M\u00e9dicas SA (Rimsa) for $2.3 billion to strengthen its presence in Latin America.",
        "date": "10012015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva Pharm to buy Mexican drugmaker Rimsa for $2.3 billion "
    },
    {
        "content": "Sept 28 Drugmaker Allergan Plc said it expected revenue to be greater than $8 billion in the second half as it completes the sale of its generics business to Teva Pharmaceuticals Industries Ltd .",
        "date": "09282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Allergan forecasts 2nd-half revenue above $8 bln "
    },
    {
        "content": "TEL AVIV  Oct 1 Teva Pharmaceutical Industries  has struck a deal to buy Mexican drugmaker Representaciones e Investigaciones M\u00e9dicas SA (Rimsa) for $2.3 billion to strengthen its presence in Latin America.",
        "date": "10012015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva Pharm to buy Mexican drugmaker Rimsa for $2.3 bln "
    },
    {
        "content": "TEL AVIV  Oct 1 Teva Pharmaceutical Industries  has agreed to acquire Representaciones e Investigaciones M\u00e9dicas SA (Rimsa)  a leading drugmaker in Mexico  for $2.3 billion.",
        "date": "10012015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm to buy Mexican drug firm Rimsa for $2.3 bln "
    },
    {
        "content": "NEW YORK Teva Pharmaceutical Industries Ltd's  research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications  given the mounting anger over the high cost of therapies in the United States.",
        "date": "09292015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Drug industry must address image problem over prices: Teva executive "
    },
    {
        "content": "Lawyers who represented drug wholesalers and retailers in an antitrust suit against Teva Pharmaceutical Industries are asking for $140.8 million in legal fees out of a $512 million settlement.",
        "date": "09182015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Lawyers seek $140.8 mln in fees from $512 mln Provigil deal "
    },
    {
        "content": "Aug 5 Perrigo Co Plc on Wednesday made a fresh case for rejecting a $34 billion offer from generic drugmaker Mylan NV and said Mylan's recent share price plunge reinforces Perrigo's intention to remain independent.",
        "date": "08052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Perrigo CEO says no easy path for Mylan to acquire company "
    },
    {
        "content": "July 27 Generic drugmaker Mylan NV won a reprieve on Monday from its unwanted suitor  Teva Pharmaceutical Industries  but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger.",
        "date": "07282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "RPT-Mylan independence from Teva's embrace comes with a price "
    },
    {
        "content": "July 28 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.",
        "date": "07282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "PRESS DIGEST- Wall Street Journal - July 28 "
    },
    {
        "content": "JERUSALEM  July 30 Teva Pharmaceutical Industries  which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal  said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition.",
        "date": "07302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's MS drug Copaxone has strong second-quarter sales "
    },
    {
        "content": "TEL AVIV Israel's Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan's generic drugs business  solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs  paying down debt and potential \"transformational\" acquisitions.",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva to buy Allergan generic business for $40.5 bln  drops Mylan bid "
    },
    {
        "content": "TEL AVIV Israel\u2019s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan\u2019s generic drugs business  solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs  paying down debt and potential \"transformational\" acquisitions. |\u00a0Video ",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to buy Allergan generic business for $40.5 billion  drops Mylan bid "
    },
    {
        "content": "July 27 Generic drugmaker Mylan NV won a reprieve on Monday from its unwanted suitor  Teva Pharmaceutical Industries  but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger.",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mylan independence from Teva's embrace comes with a price "
    },
    {
        "content": "Israeli drug maker Teva Pharmaceutical Industries Ltd   is in talks to combine with Allergan Plc's  big generic-drug business  the Wall Street Journal reported on Saturday  citing people familiar with the matter.",
        "date": "07252015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva in talks to buy Allergan big generic-drug unit: WSJ "
    },
    {
        "content": "AMSTERDAM An independent Dutch foundation linked to generic drugs manufacturer Mylan  used a poison pill to try and block a $40 billion takeover bid by Israeli rival Teva   citing potential job losses.",
        "date": "07232015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Mylan foundation tries to block Teva takeover bid with poison pill "
    },
    {
        "content": "TEL AVIV  July 26 After months of sparring in a hostile takeover bid for rival Mylan NV  Teva Pharmaceutical's move to buy Allergan Plc's  generic drug business instead could be a smoother ride that will bring bigger returns  faster.",
        "date": "07262015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Allergan bid may be healthier for Teva than battle with Mylan "
    },
    {
        "content": "NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work  possibly with another large  \"transformational\" merger.",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Allergan CEO  fresh off one deal  sets sights on others "
    },
    {
        "content": "* Teva says has power to challenge action in court   (Adds Breakingviews link  updates Mylan share price)",
        "date": "07232015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Mylan foundation tries to block Teva takeover bid with poison pill "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd  is in advanced talks to buy Allergan Plc's  generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV   according to a person familiar with the matter.",
        "date": "07262015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva nears deal for Allergan's generic drugs unit: source "
    },
    {
        "content": "July 25 Teva Pharmaceutical Industries Ltd  is in advanced talks to buy Allergan Plc's  generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV  according to a person familiar with the matter.",
        "date": "07262015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva nears deal for Allergan's generic drugs unit -source "
    },
    {
        "content": "* Combined entity to have proforma revenue of $26 bln in 2016",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 6-Teva to buy Allergan generic business for $40.5 bln  drops Mylan bid "
    },
    {
        "content": "NEW YORK  July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work  possibly with another large  \"transformational\" merger.",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Allergan CEO  fresh off one deal  sets sights on others "
    },
    {
        "content": "A whistleblower lawsuit claiming Pennsylvania pharmaceutical company Cephalon illegally promoted off-label sales of three prescription drugs will proceed after a federal judge denied the company's motion to dismiss.",
        "date": "07232015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Court allows whistleblower lawsuit vs Teva-owned company to proceed "
    },
    {
        "content": "AMSTERDAM  July 23 An independent Dutch foundation linked to generic drugs manufacturer Mylan  moved to block a takeover bid by Israeli rival Teva  the foundation said on Thursday.",
        "date": "07232015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mylan's preference shares foundation moves to block Teva's takeover bid "
    },
    {
        "content": "* Oil prices  commodities lower following China equity selloff",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "US STOCKS-Wall St drops as China stock slump stokes growth fears "
    },
    {
        "content": "July 27 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Monday:",
        "date": "07272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "July 14 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Tuesday:",
        "date": "07142015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "* Graphic: start-up capital raises: http://link.reuters.com/bag25w",
        "date": "07082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Israeli life science firms seek help to follow Teva's lead "
    },
    {
        "content": "July 6 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Monday:",
        "date": "07062015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd  is preparing to raise its bid for rival drugmaker Mylan NV  by as much as $2 billion  to $43 billion  Bloomberg reported on Monday  citing people familiar with the matter.",
        "date": "07062015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva plans to raise Mylan bid by as much as $2 billion: Bloomberg "
    },
    {
        "content": "July 6 Teva Pharmaceutical Industries Ltd  is preparing to raise its bid for rival drugmaker Mylan NV by as much as $2 billion  to $43 billion  Bloomberg reported on Monday  citing people familiar with the matter.",
        "date": "07062015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva plans to raise Mylan bid by as much as $2 bln - Bloomberg "
    },
    {
        "content": "TEL AVIV  July 1 Teva Pharmaceutical Industries  and Philips are together investing up to 100 million shekels ($26.5 million) over eight years in medical device and health technology start-ups in Israel.",
        "date": "07012015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva and Philips to jointly invest in Israeli medical device firms "
    },
    {
        "content": "NEW YORK A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone  clearing the way for the launch of a cheaper  generic version.",
        "date": "06182015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. appeals court again invalidates Teva's MS drug patent "
    },
    {
        "content": "June 19 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Friday:",
        "date": "06192015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "NEW YORK  June 18 A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd  on its top-selling multiple sclerosis drug Copaxone  clearing the way for the launch of a cheaper  generic version.",
        "date": "06182015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-U.S. appeals court again invalidates Teva's MS drug patent "
    },
    {
        "content": "June 19 Israel's Teva Pharmaceutical Industries Ltd has raised its stake in Mylan N.V. to the 4.61 percent needed for it to legally challenge Mylan's rejection of Teva's hostile takeover offer under Dutch law.",
        "date": "06192015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva raises stake in Mylan as three-way takeover battle heats up "
    },
    {
        "content": "Mylan NV's  largest stakeholder  Abbott Laboratories   said it would back Mylan's proposed acquisition of Perrigo Co Plc   potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .",
        "date": "06162015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Abbott to vote for Mylan's acquisition of Perrigo "
    },
    {
        "content": "June 16 Mylan NV's largest stakeholder  Abbott Laboratories  said it would back Mylan's proposed acquisition of Perrigo Co Plc  potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd .",
        "date": "06162015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "REFILE-UPDATE 1-Abbott to vote for Mylan's acquisition of Perrigo "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd  has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV  after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm.",
        "date": "06102015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva switches legal counsel after Mylan challenge "
    },
    {
        "content": "June 9 Teva Pharmaceutical Industries Ltd  has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV  after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm.",
        "date": "06102015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "REFILE-UPDATE 1-Teva switches legal counsel after Mylan challenge "
    },
    {
        "content": "June 9 A U.S. federal court has recommended that a preliminary injunction be issued to disqualify law firm Kirkland & Ellis LLP from advising Teva Pharmaceutical in its $40 billion attempt to take over smaller rival Mylan NV.",
        "date": "06102015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED- Judge recommends injunction to Kirkland from representing Teva "
    },
    {
        "content": "June 5 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Friday:",
        "date": "06052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "AMSTERDAM Executives at Israeli drugmaker Teva  sent an open letter to takeover target Mylan  on Monday  saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms.",
        "date": "06082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva bosses issue riposte to Mylan  praise takeover plan "
    },
    {
        "content": "June 5 Teva Pharmaceutical Industries Ltd  has increased its stake in Mylan NV to nearly 2.2 percent as it presses on with an unsolicited bid for its generic drug-making rival  a regulatory filing showed on Friday.",
        "date": "06052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva raises its stake in acquisition target Mylan "
    },
    {
        "content": "AMSTERDAM  June 8 Executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday  saying they remain committed to a deal and reiterated that Teva's $40 billion takeover proposal would benefit shareholders of both firms.",
        "date": "06082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva bosses issue riposte to Mylan  praise takeover plan "
    },
    {
        "content": "June 8 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Monday:",
        "date": "06082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "June 3 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Wednesday:",
        "date": "06032015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd  is looking to buy more shares in Mylan NV   positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid  people familiar with the matter said.",
        "date": "06022015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Exclusive: Teva poised to raise its stake in Mylan - sources "
    },
    {
        "content": "June 1 Mylan NV said Teva Pharmaceutical Industries Ltd   which has made an unsolicited offer for the company  violated U.S. anti-trust rules by acquiring a stake.",
        "date": "06012015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mylan says Teva's stake buy violates U.S. anti-trust rules "
    },
    {
        "content": "AMSTERDAM  June 8 Top executives at Israeli drugmaker Teva sent an open letter to takeover target Mylan on Monday  saying they remained committed to striking a deal and reasserting that Teva's $82-per-share offer would benefit shareholders of both firms.",
        "date": "06082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva bosses say remain committed to Mylan takeover "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd is looking to buy more shares in Mylan NV  positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid  people familiar with the matter said.",
        "date": "06022015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva poised to raise its stake in Mylan -sources "
    },
    {
        "content": "A judge in Philadelphia has refused to dismiss a whistleblower lawsuit accusing a Teva Pharmaceutical Industries Inc unit of paying kickbacks to doctors to promote off-label use of its chemotherapy drug Treanda.",
        "date": "06052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Whistleblower case over chemo drug can go ahead - judge "
    },
    {
        "content": "WASHINGTON U.S. antitrust regulators have settled a long-running fight with Cephalon  now owned by Teva Pharmaceuticals  over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil  the Federal Trade Commission said on Thursday.",
        "date": "05282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil "
    },
    {
        "content": "May 27 Teva Pharmaceutical Industries Ltd   disclosed a 1.35 percent interest in Mylan NV   saying the purchase underscored its commitment to buy Mylan as soon as possible.",
        "date": "05272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva discloses 1.35 pct stake in target Mylan "
    },
    {
        "content": "WASHINGTON  May 28 U.S. antitrust regulators have settled a long-running fight with Cephalon  now owned by Teva Pharmaceuticals  over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil  the Federal Trade Commission said on Thursday.",
        "date": "05282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil "
    },
    {
        "content": "WASHINGTON  May 28 U.S. antitrust regulators have settled a long-running fight with Cephalon  now owned by Teva Pharmaceuticals  over how it resolved a patent infringement lawsuit over the sleep disorder drug Provigil  the Federal Trade Commission said on Thursday.",
        "date": "05282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. settles 'pay for delay' fight with drugmaker Cephalon "
    },
    {
        "content": "A U.S. appeals court Friday refused to block Israeli drugmaker Teva Pharmaceutical Industries Ltd's U.S. unit from launching a generic version of Actavis PLC's osteoarthritis drug Atelvia.",
        "date": "05152015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Appeals court won't block Teva from launching generic Atelvia "
    },
    {
        "content": "Generics drugmaker Mylan NV  which is in the middle of a three-way takeover battle  has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd  but would consider buying that company down the road  Mylan Executive Chairman Robert Coury told investors this week.",
        "date": "05082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Mylan chairman tells investors he would consider buying Teva "
    },
    {
        "content": "WASHINGTON  May 4 The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's  attempt to revive patent protection for its Baraclude treatment for hepatitis B.",
        "date": "05042015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "U.S. top court rejects hepatitis B drug patent case "
    },
    {
        "content": "Generics drugmaker Mylan NV   which is in the middle of a three-way takeover battle  has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd   but would consider buying that company down the road  Mylan Executive Chairman Robert Coury told investors this week.",
        "date": "05082015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Exclusive: Mylan chairman tells investors he would consider buying Teva "
    },
    {
        "content": "California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment.",
        "date": "05072015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Top California court revives Cipro antitrust case "
    },
    {
        "content": "May 7 California's highest court on Thursday revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment.",
        "date": "05072015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Top California court revives Cipro antitrust case "
    },
    {
        "content": "* Says expects Russia business to bottom out in Q4 at the latest",
        "date": "05072015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Stada targets forex-adj Russia sales growth of 17-20 pct "
    },
    {
        "content": "April 27 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Monday:",
        "date": "04272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "JERUSALEM  April 28 A Tel Aviv court has ruled that Teva Pharmaceutical Industries violated the terms of a drug-developing licence with Israel's Proneuron Biotechnologies and has ordered it to return technology and intellectual property.",
        "date": "04282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm told to return intellectual property to Proneuron Biotechnologies "
    },
    {
        "content": "Perrigo Co Ltd  on Wednesday rejected a sweetened takeover offer from Mylan NV   while Teva Pharmaceutical Industries Ltd  said it remains committed to acquiring Mylan  in a high stakes battle of major generic drugmakers.",
        "date": "04292015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy "
    },
    {
        "content": "Mylan NV  rejected Teva Pharmaceutical Industries Ltd's  $40 billion takeover offer on Monday  saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed \"high-risk\" Teva stock.",
        "date": "04272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mylan says Teva offer too low; criticizes stock  growth prospects "
    },
    {
        "content": "* Teva responds to Mylan rejection   (Adds details from Teva letter to Mylan  updates shares)",
        "date": "04292015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 4-Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy "
    },
    {
        "content": "April 27 Mylan NV rejected Teva Pharmaceutical Industries Ltd's $40 billion takeover offer on Monday  saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed \"high-risk\" Teva stock.",
        "date": "04272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 4-Mylan says Teva offer too low; criticizes stock  growth prospects "
    },
    {
        "content": "April 30 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Thursday:",
        "date": "04302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "April 27 Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer  saying it \"grossly undervalues\" the company.",
        "date": "04272015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Mylan rejects Teva's $40 bln offer "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries  raised its 2015 earnings forecast after beating first-quarter estimates  and said it would devote \"all necessary resources\" to its $40 billion-plus bid for rival Mylan Inc .",
        "date": "04302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva lifts 2015 earnings forecast as pursues Mylan bid "
    },
    {
        "content": "* Teva shares down 1.2 pct in New York   (Adds comments on Mylan  Copaxone  analyst  shares)",
        "date": "04302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva lifts 2015 earnings forecast as pursues Mylan bid "
    },
    {
        "content": "NEW YORK Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market  including drugs in short supply  according to industry experts and a Reuters review of regulatory filings.",
        "date": "04242015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Drug overlaps  shortages may complicate Teva bid for Mylan "
    },
    {
        "content": "NEW YORK  April 24 Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market  including drugs in short supply  according to industry experts and a Reuters review of regulatory filings.",
        "date": "04262015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "RPT-DEALTALK-Drug overlaps  shortages may complicate Teva bid for Mylan "
    },
    {
        "content": "* Confident in our ability to defend patent on 40 mg Copaxone   Further company coverage:    (Reporting By Steven Scheer and Tova Cohen)",
        "date": "04302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharm on protecting Copaxone 40 mg patent "
    },
    {
        "content": "NEW YORK  April 24 Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market  including drugs in short supply  according to industry experts and a Reuters review of regulatory filings.",
        "date": "04242015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "DEALTALK-Drug overlaps  shortages may complicate Teva bid for Mylan "
    },
    {
        "content": "Generic drugmaker Mylan NV said on Friday it would take its $31 billion offer for Perrigo Co Plc directly to shareholders  in what is set to be one of the most high-profile hostile takeover attempts of the year.",
        "date": "04242015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Generic drugmaker Mylan goes hostile in bid for Perrigo "
    },
    {
        "content": "April 30 Teva Pharmaceutical Industries  TEVA.N> CEO Erez Vigodman says:",
        "date": "04302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva CEO on Mylan bid "
    },
    {
        "content": "April 22 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Wednesday:",
        "date": "04222015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "LONDON  April 24 Worldwide dealmaking in the healthcare sector has doubled this year compared with the same time in 2014  buoyed by Teva Pharmaceuticals Industries'  unsolicited $40 billion bid for smaller rival Mylan  this week  Thomson Reuters data shows.",
        "date": "04242015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Global healthcare M&A doubles versus 2014 "
    },
    {
        "content": "TEL AVIV  April 30 Teva Pharmaceutical Industries  which is seeking to acquire rival Mylan Inc  for over $40 billion  posted higher first quarter net profit that beat analysts' estimates and raised its full year outlook.",
        "date": "04302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm Q1 profit beats forecasts  raises 2015 outlook "
    },
    {
        "content": "April 22 Teva Pharmaceutical Industries Ltd   said on Wednesday it could \"promptly\" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV.",
        "date": "04222015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva ready to divest operations to win regulatory nod for Mylan buy "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan.",
        "date": "04192015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva shares slide on generic Copaxone fears "
    },
    {
        "content": "The U.S. Supreme Court on Monday vacated a federal appeals court decision that had revived patent infringement claims against Marvell Technology Group by second-guessing a lower court's interpretation of the patent's meaning and scope.",
        "date": "04202015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Supreme Court tells appeals court to review patent under Teva "
    },
    {
        "content": "Some of the top investors at Mylan NV  including Paulson & Co  are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc  according to people familiar with the matter.",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Top Mylan shareholders seek deal with Teva: sources "
    },
    {
        "content": "TEL AVIV Israeli turnaround specialist Erez Vigodman  the chief executive of Teva Pharmaceutical Industries   is looking to pull off the ultimate transformation with the biggest deal in Israel's corporate history.",
        "date": "04222015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's turnaround CEO sets sights on $40 billion mega-deal "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc  which Teva bought in 2011  used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil.",
        "date": "04202015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to pay $512 mln to settle claims of delayed generic Provigil "
    },
    {
        "content": "Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc  which Teva bought in 2011  used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil.",
        "date": "04202015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to pay $512 million to settle claims of delayed generic Provigil "
    },
    {
        "content": "TEL AVIV/NEW YORK Teva Pharmaceutical Industries Ltd on Tuesday made an unsolicited $40 billion offer for smaller rival Mylan NV  a bold bid for growth as its lucrative Copaxone drug faces generic competition. |\u00a0Video ",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Generic drugmaker Teva makes $40 billion offer for rival Mylan "
    },
    {
        "content": "* Yahoo  Chipotle down after the bell following quarterly reports",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "US STOCKS-Earnings cloud drags down Dow; Nasdaq gains on biotech M&A "
    },
    {
        "content": "April 22 Generic drugmaker Teva Pharmaceutical Industries Ltd  said it could \"promptly\" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV.",
        "date": "04222015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Teva ready to divest operations to win regulatory nod for Mylan buy "
    },
    {
        "content": "A subsidiary of Israeli drugmaker Teva has lost a bid to prevent the U.S. Federal Trade Commission from getting monetary damages in a lawsuit claiming it made \"pay for delay\" deals to suppress generic competition with its narcolepsy drug Provigil.",
        "date": "04152015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Teva unit may face disgorgement in FTC reverse payment case "
    },
    {
        "content": "Generic drugmaker Mylan NV moved quickly on Friday to pour cold water on published reports that Teva Pharmaceuticals Industries is considering a bid to acquire it.",
        "date": "04172015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Mylan says merger with Teva would be bad fit "
    },
    {
        "content": "April 20 Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc  which Teva bought in 2011  used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil.",
        "date": "04202015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-Teva to pay $512 mln to settle claims of delayed generic Provigil "
    },
    {
        "content": "April 20 Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc  which Teva bought in 2011  used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil  according to court papers.",
        "date": "04202015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "CORRECTED-UPDATE 1-Teva to pay $512 mln to settle claims of delayed generic Provigil "
    },
    {
        "content": "April 21 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Tuesday:",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "TEL AVIV/NEW YORK  April 21 Teva Pharmaceutical Industries Ltd on Tuesday made an unsolicited $40 billion offer for smaller rival Mylan NV  a bold bid for growth as its lucrative Copaxone drug faces generic competition.",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 6-Generic drugmaker Teva makes $40 billion offer for rival Mylan "
    },
    {
        "content": "* Dow off 0.45 pct  S&P down 0.1 pct  Nasdaq up 0.48 pct   (Updates to afternoon)",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "US STOCKS-Wall St mixed as doubts about earnings offset biotech M&A bid "
    },
    {
        "content": "April 22 Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.",
        "date": "04222015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Abbott says its payoff from Mylan deal surged "
    },
    {
        "content": "Teva Pharmaceutical Industries  has offered to buy rival generic drugmaker Mylan  for $40 billion in what would be the largest acquisition in Israel's history  equivalent to nearly 15 percent of GDP.",
        "date": "04222015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Factbox: Teva Pharmaceutical's history of key acquisitions "
    },
    {
        "content": "April 17 Generic drugmaker Mylan NV  moved quickly on Friday to pour cold water on published reports that Teva Pharmaceuticals Industries is considering a bid to acquire it.",
        "date": "04172015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Mylan says merger with Teva would be bad fit "
    },
    {
        "content": " ",
        "date": "04172015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva considering potential bid for Mylan - Bloomberg "
    },
    {
        "content": "* Dow off 0.33 pct  S&P down 0.05 pct  Nasdaq up 0.47 pct   (Updates to early afternoon)",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "US STOCKS-Wall St mixed as lackluster earnings offset biotech M&A bid "
    },
    {
        "content": "* Dow off 0.4 pct  S&P down 0.15 pct  Nasdaq up 0.4 pct   (Updates to midday  adds comment  updates prices)",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "US STOCKS-Wall St mixed as earnings offset merger news "
    },
    {
        "content": "* Mega-deal follows several large acquisitions in last two decades",
        "date": "04222015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "REFILE-Teva's turnaround CEO sets sights on $40 bln mega-deal "
    },
    {
        "content": "The U.S. Supreme Court on Friday will weigh whether to take a case in which chipmaker Marvell Technology Group had thought it escaped liability over a Bluetooth-related patent  only to be put on the hook again by a U.S. appeals court.",
        "date": "04142015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Marvell Semiconductor asks high court to review case under Teva standard "
    },
    {
        "content": "The U.S. Food and Drug Administration approved on Thursday the first generic version of Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug  Copaxone.",
        "date": "04162015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "FDA approves first generic version of Teva MS drug Copaxone "
    },
    {
        "content": "* Dow components Verizon  DuPont and United Tech beat estimates",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "US STOCKS-Wall St set to rise as results beat low expectations "
    },
    {
        "content": "TEL AVIV  April 21 Shares in generic drugmakers Teva Pharmaceutical Industries and Mylan jumped in pre-market trade in New York on a report from Bloomberg that Teva could make a public unsolicited offer for Mylan as soon as Tuesday.",
        "date": "04212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva declines to comment on report it to make offer for Mylan "
    },
    {
        "content": "April 16 The U.S. Food and Drug Administration approved on Thursday the first generic version of Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug  Copaxone.",
        "date": "04162015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 2-FDA approves first generic version of Teva MS drug Copaxone "
    },
    {
        "content": "April 16 Momenta Pharmaceuticals Inc  said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's  top-selling multiple sclerosis drug  Copaxone.",
        "date": "04162015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "FDA approves first generic version of Teva's MS drug Copaxone "
    },
    {
        "content": "TEL AVIV Israel's Teva Pharmaceutical Industries said it would buy U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc for an equity value of $3.5 billion to boost its portfolio of treatments for the central nervous system.",
        "date": "03302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion "
    },
    {
        "content": "* Auspex shares up 41.7 pct  Teva up 3 pct   (Adds analysts' comments  updates Teva share price)",
        "date": "03302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-Teva to buy U.S. drug developer Auspex Pharma for $3.5 bln "
    },
    {
        "content": "March 30 The following bids  mergers  acquisitions and disposals were reported by 1400 GMT on Monday:",
        "date": "03302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "* M&A deal lifts sentiment; UnitedHealth unit to buy Catamaran",
        "date": "03302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "US STOCKS-Futures point to higher open on M&A activity "
    },
    {
        "content": "March 30 Israel's Teva Pharmaceutical Industries Ltd  said it would buy U.S. drug developer Auspex Pharmaceuticals Inc for $3.5 billion to boost its portfolio of treatments for the central nervous system.",
        "date": "03302015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva to buy U.S. drug developer Auspex Pharma for $3.5 bln "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  March 24 (Fitch) Fitch Ratings has assigned a 'BBB+' rating to the  unsecured Euro bond offering issued by Teva Pharmaceutical Finance Netherlands  II  B.V. (Israel) part of Teva Pharmaceuticals Industries Ltd. (Teva).  Proceeds are expected to be used for general corporate purposes. Fitch does not  expect a material change in total debt balances to result as a net effect of  this issuance  the February 2015 tender of USD-denom",
        "date": "03242015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Fitch Rates Teva's Euro Bond Offering 'BBB+' "
    },
    {
        "content": "March 4   * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and",
        "date": "03042015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia "
    },
    {
        "content": "The top U.S. patent appeals court has affirmed a district court decision allowing generic drugmaker Lupin Ltd  but not Teva Pharmaceuticals  to make generic versions of ViiV Healthcare Co's HIV drugs.",
        "date": "02122015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Appeals court rules for Lupin  against Teva over generic HIV drugs "
    },
    {
        "content": "Feb 11 Israeli drugmaker Teva Pharmaceutical Industries Inc  said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.",
        "date": "02112015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva's internal investigation finds possible corruption "
    },
    {
        "content": "TEL AVIV Teva Pharmaceutical Industries  is ready to return to making acquisitions  it said on Thursday  after a year of focusing on costs under its new chief executive.",
        "date": "02052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "Israeli drugmaker Teva eyes acquisitions after year of cuts "
    },
    {
        "content": "* Teva seeks growth markets  complex generics  specialty drugs",
        "date": "02052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-Israeli drugmaker Teva eyes acquisitions after year of cuts "
    },
    {
        "content": "* There might not be any generic Copaxone competition in 2015 but we assume there may be -CEO  Further company coverage:    (Reporting By Steven Scheer)",
        "date": "02052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharm CEO on generic Copaxone in 2015 "
    },
    {
        "content": "* Plans 7 drug launches in 2015 with $400 million of new revenue -CEO  Further company coverage:    (Reporting By Tova Cohen)",
        "date": "02052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "BRIEF-Teva Pharm plans 7 drug launches in 2015 "
    },
    {
        "content": "TEL AVIV  Feb 5 Teva Pharmaceutical Industries  reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year.",
        "date": "02052015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Teva Pharm Q4 profit  revenue meet expectations "
    },
    {
        "content": "The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's   generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium  the agency's first such approval for the drug.",
        "date": "01282015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "FDA approves Teva's generic version of AstraZeneca's Nexium "
    },
    {
        "content": "Jan 26 The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's   generic version of AstraZeneca Plc's   Nexium to treat acid reflux  the agency's first generic approval for the drug.",
        "date": "01262015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "FDA approves Teva's generic version of AstraZeneca's Nexium "
    },
    {
        "content": "Jan 26 The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's   generic version of AstraZeneca Plc's  blockbuster heartburn drug Nexium  the agency's first such approval for the drug.",
        "date": "01262015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 1-FDA approves Teva's generic version of AstraZeneca's Nexium "
    },
    {
        "content": "(Corrects dateline) Jan 21 Natco Pharma Ltd :  * The US supreme court has remanded case relating to Teva's US patent no",
        "date": "01212015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "topStory",
        "symbol": "TEVA",
        "title": "REFILE-BRIEF-Natco Pharma says US Supreme Court remanded case relating to Teva's US patent to Court of Appeals "
    },
    {
        "content": "WASHINGTON The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone  dealing a blow to generic drugmakers looking to market a cheaper rival product.",
        "date": "01202015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "Supreme Court rules for Teva over MS drug patent "
    },
    {
        "content": "WASHINGTON  Jan 20 The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd   can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone  dealing a blow to generic drugmakers looking to market a cheaper rival product.",
        "date": "01202015",
        "name": "Teva Pharmaceutical Industries Limited",
        "news_type": "normal",
        "symbol": "TEVA",
        "title": "UPDATE 3-U.S. Supreme Court rules for Teva over MS drug patent "
    }
]